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Abstract 
The current recommendations by the American Heart Association for health 
promotion are that all persons should partake in regular physical activity in 
order to reduce the risk of cardiovascular disease. Regular physical exercise 
reduces blood pressure and is an important component of the management of 
hypertension. It is therefore important that patients with hypertension 
participate in habitual physical exercise. Many hypertensive patients who 
exercise will require anti-hypertensive medication. However, some anti-
hypertensive agents cause fatigue during exercise. In order for patients to gain 
the full benefits of an active lifestyle, it is important that the prescribed anti-
hypertensive agent does not prevent them performing and enjoying sustained 
exercise. 
It has been well documented that B-blockers cause premature fatigue during 
physical exercise. The effects on exercise performance of other first line anti-
hypertensive medications, such as calcium channel antagonists have not been 
extensively investigated. In particular, the effects of these agents on prolonged 
submaximal exercise endurance have not been well studied. 
The object of this thesis was to compare the effects of isradipine, a 
dihydropyridine calcium channel antagonist, to those of atenolol, a ~1-selective 
antagonist, on maximal and submaximal exercise performance and on short 
duration high-intensity exercise in physically active hypertensive patients. 
The study design was a crossover trial where drug treatments were double 
blinded and randomised. Physically active volunteers with mild to moderate 
hypertension were recruited. 11 subjects performed i) progressive exercise to 
exhaustion for determination of maximal oxygen consumption (V02max), 
maximal work load and cardiorespiratory responses to maximal exercise, ii) 
prolonged submaximal exercise for determination of exercise endurance, 
cardiorespiratory responses and ratings of perceived exertion (APE), and iii) 
short duration, high intensity exercise consisting of a 30 second maximal 
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exercise test (Wingate test) to determine skeletal muscle power output, 
following 4 weeks ingestion of isradipine (2.5mg bd), atenolol (50mg bd) or 
placebo. 
Diastolic blood pressure at rest was reduced by both atenolol and isradipine, 
but was lowered to a greater extent by atenolol (83.3 vs 89.0 vs 96.1 mmHg, 
atenolol vs isradipine vs placebo, p<.0005). Systolic blood pressure at rest 
tended to be similarly reduced by both agents, but was significantly reduced 
during maximal and submaximal exercise by atenolol only (p<.001 ,atenolol vs 
isradipine, placebo). Heart rate at rest and during maximal and submaximal 
exercise was decreased by atenolol only (p<.0005, atenolol vs isradipine, 
placebo). 
Maximal exercise performance was reduced after atenolol ingestion compared 
to placebo but not after isradipine ingestion. Peak workload achieved during 
the maximal exercise test was decreased after atenolol but unchanged after 
isradipine ingestion(214 vs 243 W, atenolol vs placebo, p<.01). Similarly, 
V02max was reduced after atenolol compared to placebo but was unchanged 
after isradipine ingestion (33.6 vs 36.4, 33.6 vs 36.1 mlOikg/min, atenolol vs 
placebo, atenolol vs isradipine, p<.05). 
Both atenolol and isradipine ingestion reduced submaximal endurance time 
compared to placebo (27.8 vs 46.4, 34.4 vs 46.4 min, atenolol vs placebo, 
isradipine vs placebo, p<.005), and increased rating of perceived exertion 
(APE) after 30 min of submaximal exercise (p<.05). Submaximal oxygen 
consumption (V02), ventilation, respiratory exchange ratio (REA) and blood 
lactate, glucose and free fatty acid concentrations were not altered after the 
ingestion of either agent. 
Neither agent influenced peak skeletal muscle power, total work done, or rate 
of fatigue during the Wingate test compared to placebo. 
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The results of these studies indicate that impaired performance and increased 
RPE during submaximal exercise after ingestion of either atenolol or isradipine 
is not due to alterations of ventilation, V02, RER, or blood lactate, glucose and 
free fatty acid concentrations during prolonged submaximal exercise. Similarly, 
reduced submaximal exercise performance after atenolol or isradipine 
ingestion is not due to factors which would also limit the ability of skeletal 
muscle to perform short duration, high intensity exercise before a bout of 
prolonged exercise. 
This study demonstrates that prolonged submaximal exercise testing can 
reveal an impairment in exercise performance after ingestion of anti-
hypertensive medication which is not evident during maximal exercise testing. 
This finding is important as prolonged submaximal exercise is the form of 
exercise which most hypertensive patients actually perform. 
Further research is required on the effects of anti-hypertensive medications on 
submaximal exercise performance before firm recommendations can be made 
regarding medications most suitable for the physically active hypertensive 
patient. 
The results of these and other studies indicate that it is not yet possible to 
make claims that the calcium channel antagonist agents are without effect on 
physical exercise performance in physically active hypertensive patients. 
vi 
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Chapter 1. Introduction. 
Regular physical activity has been shown to reduce all-cause mortality 
(Paffenbarger et al. 1986). In particular, regular physical activity has beneficial 
effects in reducing the risk of cardiovascular disease (Powell et al. 1987) and of 
sudden death ( Siskovick et al. 1982, 1984). Habitual exercise reduces blood 
pressure (Arroll & Beaglehole 1992; Kelley & McClellan 1994), and reduces the 
risk of cardiovascular disease independently of its effect on blood pressure 
(Paffenbarger et al. 1984). In addition, regular physical activity helps control 
obesity and favourably influences blood lipid abnormalities (Findlay et al. 1987; 
Stamford et al. 1984). There is thus ample reason for the American Heart 
Association (1992) to advocate participation in regular physical exercise for 
persons of all ages to promote health and prevent disease. 
More specifically, regular physical activity is recognised as an important 
component of the management of essential hypertension. The introduction of a 
physical exercise program can be sufficient to control mild hypertension 
(Houston 1992; Kaplan 1985). However, as non-pharmacological methods of 
blood pressure control exert only modest reductions in blood pressure (Arroll & 
Beaglehole 1992; Grobbee & Hofman 1986), most patients with moderate or 
severe hypertension who participate in regular physical activity will require anti-
hypertensive medication for adequate blood pressure control. These patients 
therefore require medication which would allow them to perform and enjoy 
regular, sustained physical activity so that the health benefits of exercise can 
be attained. 
Beta-blockers are commonly used in the management of hypertension yet they 
impair both maximal and sub-maximal exercise performance (Gordon & 
Duncan 1991; Gullestad et al. 1989a; Van Bertel & Van Baak 1992). Patients 
treated with these agents frequently complain of fatigue during exercise (Van 
Bertel & Van Baak 1992). Furthermore, ratings of perceived exertion during 
submaximal exercise are increased after p-blockade (Derman et al. 1992). 
Thus, patients treated with ~-blockers are less able to perform and enjoy 
physical activity than those not ingesting these agents. 
The prescription of anti-hypertensive agents, such as ~-blockers, which impair 
exercise performance to patients who participate in regular physical activity 
may therefore lead to non-compliance. Medication may be ingested 
intermittently or not at all to allow for "medication free" competition or 
participation in exercise. Therefore, when prescribing anti-hypertensive agents 
for individuals with hypertension who participate in competitive exercise, it is 
important to know the effects of these medications on exercise capacity. 
The effects of ~-receptor blockade on exercise performance have been well 
studied (Gordon & Duncan 1991; Kaiser 1984; Tesch 1985; Van Baak 1988). 
However, the effects of other first line anti-hypertensive agents, such as 
calcium channel antagonists and ACE inhibitors, on exercise performance 
have not been equally well investigated. 
Calcium channel antagonists are now established as important drugs in the 
first line treatment of hypertension (Halperin & Cubeddu 1986). These agents 
are safe, effective, well tolerated and cause few metabolic disturbances 
(Kaplan 1989; Man in't Veld 1989; Messerli et al. 1988). Calcium channel 
antagonists inhibit cardiac and smooth muscle contraction by reducing calcium 
influx into the muscle cell. This leads to peripheral vasodilatation and a fall in 
arterial blood pressure (Messerli et al. 1988). Calcium channel antagonists can 
be classified into two groups on the basis of tissue specificity; verapamil-like 
drugs which have negative inotropic and chronotropic effects with mild 
peripheral vascular effects, and dihydropyridine derivatives, including 
nifedipine, which have lesser cardiac and more marked peripheral vasodilatory 
effects (Kaplan 1989; Man in't Veld 1989). 
The influence of dihydropyridine calcium channel antagonists on physical 
exercise capacity has not been thoroughly investigated. Nifedipine, a 
dihydropyridine calcium channel blocker, decreases maximal exercise capacity 
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in normotensive subjects (Andersen & Vik-mo 1984; Chick et al. 1986; Derman 
et al. 1992; Duffey et al. 1984; Gordon et al. 1986, 1987), but no reduction in 
maximal exercise performance occurs in hypertensive subjects (Ashmore et al. 
1990; Gosse et al. 1992; Halperin et al. 1993). Whether these differences are 
due to hypertension per se or due to other factors including the physical activity 
status of the subjects or methodological problems is unclear. 
Previous investigations from our laboratory have demonstrated that the 
dihydropyridine derivative, isradipine, reduced submaximal exercise tolerance 
in normotensive subjects (Selvey 1991 ). However, the dihydropyridine 
derivative, amlodipine, had no effect on submaximal exercise performance 
when administered to physically active hypertensive patients (Gillies et al. 
1996). There are no other reported studies of the effect of dihydropyridine 
calcium channel blockade on submaximal exercise capacity in either 
normotensive or hypertensive subjects. 
Maximal exercise testing is the most common measure of exercise 
performance which is described in the literature on drug effects on exercise. 
However, as prolonged submaximal exercise is the most common form of 
exercise performed by hypertensive patients, it is particularly important to 
investigate the effects of anti-hypertensive agents during this form of exercise. 
Furthermore, submaximal exercise testing may reveal differences between 
agents which are not revealed by maximal exercise testing (Mclenachan et al. 
1991 ). 
The emphasis on maximal oxygen consumption (V02max) as a measure of 
exercise performance stems from a belief that it is either oxygen delivery to, or 
oxygen uptake and use by, the exercising muscles which is the limiting factor in 
exercise performance (Noakes 1988). Noakes (1988) has challenged this 
belief, and suggests that it is failure of muscle contractility which determines 
the onset of fatigue. Anti-hypertensive medications which reduce exercise 
tolerance may perhaps be acting on skeletal muscle to cause premature 
fatigue. The effects of calcium channel antagonism on skeletal muscle function 
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have not previously been determined. Some indication of skeletal muscle 
function may be given by the performance of short duration, high intensity 
exercise, as measured by the Wingate test, as this test correlates well with 
skeletal muscle composition (Bar-Or 1987). 
Accordingly, this thesis investigates the effects of the dihydropyridine calcium 
channel antagonist, isradipine, on submaximal and maximal exercise 
performance, and on short duration, high intensity exercise. The effects of this 
agent are compared to the effects of the ~1-selective blocker, atenolol, and to 
the effects of placebo. 
A major haemodynamic abnormality in essential hypertension is peripheral 
vasoconstriction; this is reversed by calcium channel antagonism resulting in 
blood pressure reduction (Cody 1987; Katzman et al. 1987; Omvik et al. 1988). 
Calcium antagonists do not reduce blood pressure in normotensive individuals 
who do not have peripheral vasoconstriction (Derman et al. 1993; Omvik & 
Lund-Johansen 1988; Raffestin et al. 1985; Vanhees et al. 1988). Because of 
this difference in haemodynamic effects of calcium channel blockade between 
normotensive and hypertensive subjects, it is possible that the effects of these 
agents on exercise performance in hypertensive subjects may differ to those in 
normotensive subjects. Accordingly, this thesis investigates the effects of 
isradipine in hypertensive subjects. 
Beta-blockade causes a greater reduction in exercise tolerance in trained 
individuals compared to untrained individuals (Joyner et al. 1986). It is possible 
that a similar effect may occur in any reduction in exercise capacity seen with 
other anti-hypertensive agents. Therefore it is important to investigate the 
effects of calcium channel antagonists on exercise performance in physically 
active subjects. This study examines the effects of isradipine on exercise 
performance in patients with hypertension who participate in regular physical 
exercise. 
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Aim of this thesis 
The aim of this thesis is therefore, to examine the effects of the dihydropyridine 
calcium channel antagonist, isradipine, on maximal, prolonged submaximal 
and short duration, high intensity exercise performance in physically active 
subjects with hypertension, and to compare these effects to the effects of the 
B1-antagonist, atenolol. 
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Chapter 2. Literature review - The effects of calcium channel 
antagonists on exercise performance and the physiological 
response to exercise in normotensive and hypertensive 
individuals. 
2.1 Introduction 
Calcium channel antagonists are important drugs for the management of 
hypertension. They are safe, effective, well tolerated and cause few metabolic 
alterations (Kaplan 1989; Man in't Veld 1989; Messerli et al. 1988). This review 
summarizes the available literature on the effect of calcium channel 
antagonists on exercise performance and on the physiological response to 
exercise. 
Calcium channel antagonists act by reducing calcium flux through voltage 
sensitive calcium channels and thereby reduce the entry of extracellular 
calcium into cells during depolarisation. As these cells are dependent on the 
influx of calcium for contraction, the effect of calcium channel antagonists is to 
inhibit cardiac and smooth muscle contraction. A rise in intracellular calcium 
concentration is also necessary for conduction through the sinoatrial and 
atrioventricular nodes in the heart. Thus, calcium channel antagonists have a 
negative chronotropic and inotropic effect and cause peripheral vasodilatation. 
The vasodilatation causes a reduction in mean blood pressure (Kaplan 1989; 
Man in't Veld 1989). 
Voltage sensitive calcium channels are also found in skeletal muscle cell 
membranes and while their exact role is unknown they are thought to be 
involved in excitation-contraction coupling. The coupling occurs without calcium 
entry into the cell (Caswell & Brandt 1989; Romey et al. 1988). Verapamil has 
been shown to reduce muscle twitch amplitude in the skeletal muscle of 
anaesthetised cats (Kraynack et al. 1983) and dogs (Lawson et al. 1983) 
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suggesting that it possesses a neuromuscular blocking action. Clinically 
significant neuromuscular blocking action by verapamil has not been reported. 
However the neuromuscular junction remains a site where calcium antagonists 
could potentially impair skeletal muscle function. 
Calcium blockers can be classified into two groups on the basis of tissue 
specificity; firstly, verapamil and diltiazem like drugs which have marked 
cardiac effects and mild peripheral vascular effects, and secondly, the 
dihydropyridine derivatives (including nifedipine), which have lesser cardiac 
and more marked peripheral vasodilatory effects (Kaplan 1989; Man in't Veld 
1989). Because of the difference between these two classes of agents the 
effects of each on exercise parameters will be discussed separately. 
Most studies of the effects of the calcium antagonists involving exercise have 
examined the effects of these agents on the cardiovascular system. Exercise is 
used to stress the cardiovascular system in order that any latent effects of the 
drug on the cardiovascular system can be measured. The performance of 
exercise per se has not been considered important and indeed, is frequently 
not measured (Cody 1987; D'Agostino et al. 1983; Jones et al. 1983; Katzman 
et al. 1987; Omvik et al. 1988). Even fewer studies examine other variables 
which may potentially affect exercise performance (including glucose 
metabolism and thermoregulation ). To date, no studies have measured the 
effect of these agents on skeletal muscle strength. 
The exercise protocols used and the parameters measured vary greatly 
between the reported studies. Although the studies report the effects of 
calcium channel antagonists, different drugs with varying efficacies and doses 
are used for different periods of time and via different methods of 
administration. All these factors make direct comparisons of the results of 
these studies difficult (Ashmore et al. 1990; Chick et al. 1986; D'Agostino et al. 
1983; Derman et al. 1992; Gordon et al. 1987; Halperin et al. 1993; Jones et al. 
1983; Katzman et al. 1987; Myburgh et al. 1987; Raffestin et al. 1985). 
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The primary haemodynamic abnormality in essential hypertension is raised 
systemic vascular resistance (Cody 1987; Katzman et al. 1987; Lund-Johansen 
1985). This results in a raised mean arterial pressure. During exercise, 
hypertensive subjects have a fall in total peripheral resistance (TPR), but it 
remains higher than normal, resulting in raised TPR and mean arterial pressure 
during exercise. Hypertensive subjects have a lower cardiac index (Cl) and 
stroke volume index (SVI) at rest and during exercise than subject without 
hypertension (Cody 1987; Lund-Johansen 1987). Calcium channel blockers 
cause vasodilatation and therefore have the potential to reverse these 
haemodynamic effects. 
In normotensive subjects however, where TPR is not raised, neither systolic 
nor diastolic blood pressure (BP) is reduced by calcium channel antagonists 
(D'Agostino et al. 1983; Derman et al. 1992; Petri et al. 1986; Raffestin et al. 
1985; Vanhees et al. 1988). Because of the different effects of calcium channel 
blockers on BP in normotensive and hypertensive individuals, and because 
alterations in BP could possibly influence exercise capacity, the effects of 
these agents on exercise performance in normotensive and hypertensive 
subjects will be discussed separately. 
2.2 Verapamil and Diltiazem 
2.2.1 Verapamil and diltiazem in normotensive subjects 
2.2.1.1 Exercise performance in normotensive subjects 
In normotensive subjects, progressive exercise tests to exhaustion have failed 
to show any effect of verapamil or diltiazem on maximum oxygen uptake 
(V02max), maximal workload (Wlmax), exercise duration or ratings of 
perceived exertion (RPE) (Derman et al. 1991 b; Gordon et al. 1986; Petri et al. 
1986; Vanhees et al. 1988). 
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Submaximal exercise performance in normotensive individuals is not effected 
by the administration of verapamil or diltiazem (Derman et al. 1991 b; 
Herbertsson & Fagher 1990; Vanhees et al. 1988). 
Derman et al. (1993) examined the effects of diltiazem (30mg tds) given for 
one week on isokinetic skeletal muscle function. Diltiazem had no effect on 
peak power, average power and work done at a variety of contraction velocities 
during 1 O second tests, or on total work done and rate of work decline during a 
30 second test. 
Hence, studies to date indicate that neither verapamil nor diltiazem 
administered to normotensive subjects alters maximal or submaximal exercise 
performance, and diltiazem does not alter isokinetic exercise performance. 
2.2.1.2 Cardiovascular, respiratory, metabolic and hormonal parameters 
following verapamil or diltiazem administration in normotensive subjects 
The influence of verapamil and diltiazem administration in normotensive 
subjects on cardiovascular parameters at rest and during exercise is shown in 
Table 2.1. Verapamil and diltiazem in moderate doses do not alter systolic or 
diastolic BP or heart rate (HR) at rest or during maximal, submaximal dynamic 
or isometric exercise in normotensive subjects (D'Agostino et al. 1983; Derman 
et al. 1991 b, 1993; Gordon et al. 1986; Petri et al. 1986; Stein et al. 1984; 
Table 2.1 Influence of verapamil and diltiazem in normotensive subjects on cardiovascular 
parameters at rest an d d . . unna exercise. 
BPrest HRre~t BPmxex HRmxex BP submx HR~nbmx BPiso HRiso 
Verapamil H7,8,9 H6,7,8,9 H7,9 H5,9 H1,5,9 H1,5,9 H8 H8 
_J,5• -l..7,8 _J,5# _J,5' 
Diltiazem H3,4 H3,4 H3,5 H2,3,5 
* ' Diastolic BP at high dose (320mg daily) only, Systolic BP at high dose only, High dose only 
1-D'Agostino et al. 1983, 2-Derman et al. 1992, 3-Derman et al. 1991 b, 4-Derman et al. 1993, 5-
Gordon et al. 1986, 6-Herbertsson & Fagher 1990, 7-Petri et al. 1986, 8-Stein et al. 1984, 9-Vanhees 
et al. 1988. 
Abbre_viations: BPrest= systolic and diastolic blood pressure at rest, HRrest= heart rate at rest, BP mxex= 
systolic blood pressure at maximal exercise, HRmxex= maximal heart rate, BPsubmx= systolic and 
diastolic blood pressure during submaximal exercise, HRsub x= heart rate during submaximal 
exercise, BP. = systolic and diastolic blood pressure during isometric exercise, HR. = heart rate 
, , ISO, , ISO 
during isometric exercise. 
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Vanhees et al. 1988). High doses only of verapamil (320mg daily) may reduce 
HR and mean BP during submaximal exercise in healthy individuals 
(Herbertsson & Fagher 1990). 
Minute ventilation (Vi), respiratory exchange ratio (RER), carbon dioxide 
production (VC02) and blood lactate concentrations during maximal and 
submaximal exercise were unchanged after verapamil or diltiazem 
administration compared to placebo in normotensive subjects (Derman et al. 
1991 b; Gordon et al. 1986; Petri et al. 1986; Stein et al. 1984; Vanhees et al. 
1988). Blood glucose, glycerol, free fatty acids (Petri et al. 1986), potassium, 
and noradrenaline (Stein et al. 1984) concentrations during maximal exercise 
testing are similarly unaltered following verapamil administration. Similarly, 
serum concentrations of potassium, glucose, free fatty acids, triglycerides and 
growth hormone during submaximal exercise were unchanged by diltiazem 
administration (Derman et al. 1992). 
Thus, in normotensive subjects, it appears that verapamil and diltiazem to not 
alter exercise performance. There may be a reduction of around 15 bpm in 
maximal HR with verapamil but this is not a consistent finding. High doses of 
verapamil may reduce HR and systolic BP during submaximal exercise. 
Plasma concentrations of hormones and carbohydrate and fat metabolites 
during exercise are not altered by these two agents. The study by Herbertsson 
& Fagher (1990), where ingestion of verapamil resulted in decreased HR and 
mean BP but no reduction in submaximal exercise performance, is evidence 
against the argument that alterations in central haemodynamics cause the 
decreased exercise capability seen after ~-blockade. 
2.2.2 Verapamil and diltiazem in hypertensive subjects 
2.2.2.1 Exercise performance in hypertensive subjects 
Administration of oral verapamil to hypertensive patients has no effect on 
V02max, maximal exercise duration or maximal workload (Ashmore et al. 
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1990; Cody et al. 1986, Halperin et al. 1993). Diltiazem had no effect on 
V02max, maximal exercise test duration or RPE during a maximal test when 
administered to hypertensive patients over periods ranging from 2 to 16 weeks 
(Kelemen et al. 1989; Luurila et al. 1987; Myburgh & Gordon 1987; Szlachcic 
et al. 1987; Yamakado et al. 1983). The study by Myburgh & Gordon (1987) 
involved physically active subjects with a mean age of 33 years. Gosse et al. 
(1992) and Pool et al. (1985) reported that exercise duration during a maximal 
exercise test was increased in hypertensive patients after oral verapamil and 
diltiazem respectively. However, in both these studies, there was no difference 
in maximal exercise test duration between the treatment and control groups. 
There were also methodological weaknesses in these studies in that the 
physical exercise practices of the subjects were not controlled and there was 
the possibility of habituation to the test as the subjects were initially sedentary. 
Mooy et al. ( 1987) found that 4 weeks of verapamil treatment in hypertensive 
patients had no effect on time to exhaustion during submaximal exercise. No 
other studies have reported on submaximal exercise performance in 
hypertensive subjects ingesting verapamil or diltiazem. 
2.2.2.2 Cardiovascular, respiratory, metabolic and hormonal parameters 
following verapamil or diltiazem administration in hypertensive subjects 
The influence of verapamil and diltiazem on cardiovascular parameters at rest 
and during exercise in hypertensive subjects is shown in Table 2.2. Systolic 
and diastolic BP at rest and during exercise is reduced after the ingestion of 
verapamil and diltiazem by hypertensive subjects (Ashmore et al. 1990; Gosse 
et al. 1992; Gould et al. 1982; Halperin et al 1993; Lund-Johansen 1985), 
although the hypotensive effect of these agents may be lost at high exercise 
intensities (Yamakado et al. 1983). Resting heart rate when supine is 
unchanged after verapamil or diltiazem administration in hypertensive subjects 
(Halperin et al. 1993; Lund-Johansen 1985; Mooy et al. 1987; Pool et al. 1985). 
However, heart rate while standing at rest, and during exercise, is reduced in 
hypertensive subjects after verapamil or diltiazem administration (Gosse et al. 
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Table 2.2 Influence of verapamil and diltiazem in hypertensive subjects on cardiovascular 
:>arameters at rest an d dunno exercise. 
BPrest HRsuoine HR.+•nd BPmxex HRmxAx BPsubmax HRsubmax 
Verapamil .!-6 H1,5,8,1Q .!-8, 10 .!-1,3,5 .!-1,5 .!-1,4,5,8 .!-1,5,8,10,15 
H2* H2* .!-10# H2* 
Diltiazem .!-6 H7,13,14,16 .!-13, 16 .!-9", 13 .!-11, 13, 16 .!-11, 12, 13, 14, 16 .!-7,11,12,13,16 
.!-11,12 H16 H14 .!-7',9# H14 
* 
.. 
Short term study, D1astohc BP only. 
1-Ashmore et al. 1990, 2-Cody et al. 1986, 3-Gosse et al. 1992, 4-Gould et al. 1982, 5-Halperin et 
al 1993, 6-Kaplan 1989, ?-Klein et al. 1983, a-Lund-Johansen 1985, 9-Luurila et al. 1987, 10-Mooy 
et al. 1987, 11-Myburgh & Gordon 1987, 12-0mvik & Lund-Johansen 1988, 13-Pool et al. 1985, 
14-Szlachcic et al. 1987, 15-Van Baak et al. 1987b, 16-Yamakado et al. 1983. 
Abbreviations: BP ,= systolic and diastolic blood pressure at rest, HR . = heart rate while res supine . 
supine, HR 
I 
d= heart rate while standing, BP = systolic blood pressure at maximal exercise, san mxex . 
HR = maximal heart rate, BP b = systolic and diastolic blood pressure during submax1mal mxj!x sµ mx 
exercise, HRsubmx= heart rate during submaximal exercise. 
1992; Gould et al. 1982; Halperin et al. 1993; Kaplan 1989; Klein et al. 1983; 
Lund-Johansen 1985; Mooy et al. 1987; Myburgh & Gordon 1987; Omvik & 
Lund-Johansen 1988; Pool et al. 1985; Yamakado et al. 1983). 
The results of invasive haemodynamic investigations in hypertensive patients 
at rest and during submaximal exercise after the administration of calcium 
channel antagonists are shown in Table 2.3. Diltiazem treatment administered 
to hypertensive patients results in reduced mean arterial pressure during 
exercise due to reduced TPR during exercise, while cardiac output is 
maintained (Omvik & Lund-Johansen 1988) or even increased (Klein et al. 
Table 2.3. Influence of calcium channel antagonists in hypertensive subjects on cardiovascular 
:>arameters at rest an d d . b . I . unnq su maxima exercise. 
TPRrest SVlrest Cir"•' TPR ... hmx SVlsubmx Clsubmx 
Verapamil J,2 i2 H2 H2* H2* H2* 
Diltiazem J, 1,5 J, 1,5 i1 ,5 i1 
HS 
Nifedipine J, 1,3 H1,3 H1,3 J, 1,3 H3 i1 
i1 H3 
Nisoldipine J,5 H6 H6 H6 H6 J,5 
Amlodipine J,4 i4 H4 J,4 H4 i4 
*Small sample size, isotonic exercise. 
1-Klein et al. 1983, 2-Lund-Johansen 1985, 3-Lund-Johansen & Omvik 1983, 4-Lund-Johansen 
et al. 1992, 5-0mvik & Lund-Johansen 1988, 6-0mvik et al. 1988. 
Abbreviations: TPRres1=total peripheral resistance at rest, SVlrest=Stroke volume index at rest, 
Clres1=cardiac index at rest, TPRsubmx=total peripheral resistance during submaximal exercise, 
SVlsubmx=stroke volume index during submaximal exercise, Clsbmx=cardiac index during 
submaximal exercise. 
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1983). A reduction in TPR during exercise has not been reported after 
verapamil administration (Lund-Johansen 1985). This may be to the relatively 
small dose of verapamil used (240mg daily), which resulted in only a modest 
reduction in resting mean arterial pressure, and to the small sample size so 
that the trends were not statistically significant. 
Van Baak et al. (1987b) found that verapamil therapy given to hypertensive 
subjects was not associated with any changes in plasma glucose, lactate, free 
fatty acid or glycerol concentrations compared to placebo during submaximal 
exercise. This finding implies that hormone secretion is not altered by 
verapamil ingestion. V02 and Vi during submaximal exercise were also 
unaltered following verapamil administration compared to placebo (Van Baak 
et al. 1987b). 
Thus, reports on the effects of verapamil and diltiazem in hypertensive 
subjects, have failed to show any impairment of maximal or submaximal 
exercise performance. This is despite the fact that most studies have shown 
that systolic and diastolic BP during submaximal exercise are reduced by these 
agents when administered to hypertensive subjects. In addition, most studies 
have indicated that, in hypertensive subjects, HR is reduced during 
submaximal and maximal exercise, after verapamil and diltiazem ingestion. 
Hence, reduced BP and HR during exercise are not necessarily associated 
with an impairment in exercise capacity. 
2.3 Dihydropyridine derivatives 
2.3.1 Dihydropyridine derivatives in normotensive subjects 
Nifedipine is the only dihydropyridine derivative of which the effects during 
exercise have been investigated in normotensive subjects. 
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2.3.1.1 Exercise performance in normotensive subjects 
2.3.1.1 a Maximal exercise performance 
In most studies using normotensive subjects, V02max was unaltered following 
nifedipine ingestion compared to placebo (Chick et al. 1986; Derman et al. 
1992; Duffey et al. 1984; Gordon et al. 1987; Kindermann 1987; Raffestin et al. 
1985). However, Gordon et al. (1986) found a small but significant reduction in 
V02max after a single oral dose of 10mg of nifedipine. The significance of this 
result is unclear, as the former studies either used higher doses of nifedipine 
and/or longer periods of administration. 
Although V02max at peak exercise is unchanged following ingestion of 
nifedipine, most studies have shown a reduction in exercise test duration 
and/or Wlmax. Chick et al. (1986) found that, following nifedipine 
administration, Wlmax was decreased by 4%, with a corresponding decrease 
in exercise time, despite no change of V02max (exercise was "less efficient"). 
Derman et al. (1992) also reported a reduction in peak workload achieved and 
a decrease in time to exhaustion, without any significant change in V02max. 
Furthermore, in four other studies exercise duration was decreased (Andersen 
& Vik-mo 1984; Duffey et al. 1984; Gordon et al. 1986, 1987). Thus, it appears 
that maximal exercise capacity is impaired after nifedipine administration in 
normotensive subjects. 
2.3.1.1 b Submaximal exercise performance 
Few studies have investigated the effect of nifedipine on prolonged 
submaximal exercise endurance in healthy subjects. In the studies involving 
submaximal exercise, the subjects do not exercise to exhaustion; instead a set 
workload is used for a specified duration which is achieved by all subjects. 
Derman et al. (1992) reported that APE during submaximal exercise was 
unaltered by a single dose of 20mg of nifedipine, but was increased by atenolol 
and cilazapril. Similarly, Kindermann et al. (1987) reported that all subjects 
were able to exercise at 75% V02max for 50 minutes after ingestion of both 
nifedipine and placebo, but in a similar trial, were unable to do so following ~-
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blocker administration. These findings suggest that any alteration of 
submaximal exercise tolerance following ingestion of nifedipine is less than that 
experienced following ~-blockade. 
2.3.1.2 Cardiovascular, respiratory, metabolic and hormonal parameters 
following dihydropyridine derivative administration in normotensive 
subjects 
The influence of nifedipine in normotensive subjects on cardiovascular 
parameters at rest and during exercise is shown in Table 2.4. The effects of 
other dihydropyridine derivatives on these parameters have not been reported 
in normotensive subjects. 
Most studies report that systolic and diastolic BP and HR at rest are 
unchanged after nifedipine ingestion in normotensive subjects (Derman et al. 
1992; Kindermann et al. 1987; Raffestin et al. 1985; Stein et al. 1984). 
However, the reports of the effect of nifedipine on BP and HR during exercise 
in normotensive subjects are conflicting. Mean BP during maximal and 
submaximal exercise has been reported to be reduced after nifedipine 
administration (Andersen & Vik-mo 1984; Chick et al. 1986), although other 
authors report no change in systolic or diastolic BP during exercise after 
nifedipine ingestion (Derman et al. 1992;. Raffestin et al. 1985). During 
submaximal exercise at a mild to moderate intensity, nifedipine ingestion by 
Table 2.4. Influence of nifedipine on cardiovascular parameters at rest and during exercise in 
t . b" t normo ens1ve su 11ec s. 
BPrest HRrest BPmx ex HRmxex BPsubmx HRsubmx 
Nifedipine H3,4,8 H3,7,8,9 ,l, 1,2 H1 ,2,3,4,5,6,7,8 H3,8 i1 ,2,5,6,8 
j4 H3 ,l,9* J, 1 H1,2,3,7# 
* 
ll, . 
High dose only (20mg tds), High intensity exercise. 
1-Andersen & Vik-mo 1984, 2-Chick et al. 1986, 3-Derman et al. 1992, 4-Duffey et al. 1984, 5-
Gordon et al. 1986, 6-Gordon et al. 1987, ?-Kindermann et al. 1987, 8-Raffestin et al. 1985, 9-
Stein et al. 1984. 
Abbreviations: BPres1=systolic and diastolic blood pressure at rest, HRres1=heart rate at rest, 
BPmxex=systolic blood pressure at maximal exercise, HRmxex=maximal heart rate, BPsubmx= 
systolic and diastolic blood pressure during submaximal exercise, HRsubmx=heart rate during 
submaximal exercise. 
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normotensive subjects results in an increased HR at a given workload 
(Andersen & Vik-mo 1984; Chick et al. 1986; Gordon et al. 1986, 1987; 
Raffestin et al. 1985), but during high intensity exercise, no difference in HR 
has been documented (Andersen & Vik-mo 1984; Chick et al. 1986; Derman et 
al. 1992; Kindermann 1987). Similarly, maximal HR is reported as unchanged 
following nifedipine administration in healthy subjects (Andersen & Vik-mo 
1984; Chick et al. 1986; Derman et al. 1992; Duffey et al. 1984; Gordon et al. 
1986, 1987; Kindermann 1987; Raffestin et al. 1985). 
Andersen & Vik-mo (1984) used echocardiography to assess changes in sub-
maximal exercise haemodynamics in normotensive subjects with a single sub-
lingual dose of nifedipine compared to placebo. They found that at submaximal 
workloads, although HR was increased, the rate-pressure product was 
decreased because of a fall in systolic and diastolic BP. At high submaximal 
and maximal workloads, stroke volume was increased after administration of 
nifedipine. The authors felt that this may be explained by reduced impedance 
to systolic cardiac emptying, as a result of vasodilatation. The rise in stroke 
volume at higher workloads, combined with a rise in HR at lower workloads, 
would result in a increase in cardiac output (Andersen & Vik-mo 1984). 
Stein et al. (1984) measured haemodynamic parameters during isometric 
handgrip exercise. Heart rate and systolic and diastolic BP during isometric 
exercise were unaltered after 4 days of nifedipine ingestion in normotensive 
patients. 
Vi or REA at maximal exercise are unchanged after nifedipine ingestion in 
normotensive individuals (Chick et al. 1986; Derman et al. 1992; Gordon et al. 
1986, 1987; Raffestin et al. 1985). Similarly, V02, Vi and REA at a given 
submaximal workload are unaltered following nifedipine administration in 
healthy subjects (Derman et al. 1992; Gordon et al. 1986, 1987; Kindermann 
1987; Raffestin et al. 1985). 
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As dihydropyridine calcium channels are located on secretory cells and calcium 
channel antagonists are known to inhibit calcium dependent hormone release 
in vitro (Raffestin et al. 1985), it is possible that hormone release during 
exercise may be reduced by calcium channel blockers and that this may affect 
exercise performance. However, serum noradrenaline, growth hormone, and 
glucagon concentrations are all increased, and serum adrenaline and insulin 
concentrations are unaltered, during submaximal exercise after nifedipine 
administration (Kindermann 1987; Raffestin et al. 1985). Furthermore, serum 
noradrenaline concentration was found to be unchanged at maximum exercise 
after nifedipine ingestion, despite a higher resting concentration (Stein et al. 
1984). Thus, there is no evidence that, in normotensive subjects, hormone 
concentrations during exercise are reduced by dihydropyridine calcium channel 
antagonists. The increase in HR, noradrenaline and other blood hormone 
concentrations during exercise is thought to be due to reflex sympathetic 
stimulation, secondary to vasodilatation caused by nifedipine ingestion 
(Raffestin et al. 1985). 
Raffestin et al. (1985) also report an increase in serum glucose, ketones, 
lactate and free fatty acid concentrations during submaximal exercise following 
nifedipine administration in normotensive subjects. This was surmised by the 
authors to be due to an increased rate of glycogenolysis and lipolysis as a 
result of increased sympathetic stimulation (Raffestin et al. 1985). Chick et al. 
(1986) also found increased blood lactate concentrations during submaximal 
exercise following ingestion of nifedipine. However, other authors have failed to 
document this effect on blood lactate concentrations (Derman et al. 1992; 
Kindermann 1987). 
Thus, it appears that nifedipine does impair maximal exercise capacity in 
normotensive subjects. The cause of this small decrement in performance is 
unclear. Most studies show that HR at rest and at maximal exercise is 
unchanged after nifedipine ingestion. Mean BP at maximal exercise is probably 
reduced, but this is compensated by an increase in stroke volume resulting in 
an increased cardiac output at maximal exercise (Andersen & Vik-mo 1984). 
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This would act to maintain blood flow to active muscle despite vasodilatation. 
The concentration of serum noradrenaline, growth hormone, and glucagon 
during exercise following nifedipine ingestion in normotensive subjects is 
increased. Submaximal exercise performance after the administration of 
nifedipine to healthy individuals has, however, not been adequately 
investigated. 
2.3.2 Dihydropyridine derivatives in hypertensive subjects 
2.3.2.1 Exercise performance in hypertensive subjects 
Previous studies have found that nifedipine, lacidipine or amlodipine 
administered to patients with mild to moderate hypertension does not alter 
V02max, maximal exercise test duration or the WLmax achieved (Ashmore et 
al. 1990; Fariello et al. 1991; Gillies et al. 1996; Gosse et al. 1992; Halperin et 
al. 1993). The subjects in these studies were sedentary except in the study by 
Gillies et al. (1996), where subjects were physically active. 
Prolonged submaximal exercise performance has been found to be unaltered 
following 2 weeks of amlodipine ingestion by physically active hypertensive 
patients (Gillies et al. 1996). 
Gillies et al. (1996) examined the effects of amlodipine ingestion on skeletal 
muscle function. These authors reported that the torque produced by maximal 
voluntary isometric contraction of the quadriceps muscle in physically active 
hypertensive patients is unaltered following amlodipine ingestion. 
2.3.2.2 Cardiovascular, respiratory and hormonal parameters following 
dihydropyridine derivative administration in hypertensive subjects 
The influence of nifedipine, nicardipine, nisoldipine, isradipine, amlodipine and 
lacidipine in hypertensive subjects on cardiovascular parameters at rest and 
during exercise is shown in Table 2.5. 
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Table 2.5. Influence of dihydropyridine derivatives on cardiovascular parameters at rest and during 
. h rt b' t exercise in 1ype ens1ve su Jec s. 
BP,est HRrest BPmx ex HRmx ex BPsubmx HRsubmx 
Nifedipine .J..6,9, 10, 12, 13 H1,6,8,9,10, 12, 13 .J..1,8 H10 .J..1,6,9,13 H1,6,10,12,13 
H10 .J, 1 .J, 10*,12* 
lsradipine .J..2,3,15 H2 .J,2 H2 .J,2 
i3 .J, 15* 
Nicardipine .J..4,11,17 H4,11 .J..4, 11, 17 H4,11,17 
i17 
Lacidipine .J,5 .J,5 HS 
Nisoldipine .J..16 H16 .J..16 H16 
Amlodipine .J,14 H7,14 H7 .J, 14 H7,14 
.J,7# H7 
Nitrendipine j,5 H6 .J..6 H6 
ff ·D1astohc BP only, Systolic BP only. 
1-Ashmore et al. 1990, 2-Cantor & Cristal 1990, 3-Dvorak et al. 1991, 4-Fariello et al. 1989, 5-
Fariello et al. 1991, 6-Franz & Wiewel 1984, 7-Gillies et al. 1996, 8-Gosse et al. 1992, 9-Gould et 
al. 1982, 1 a-Halperin et al. 1993, 11-Jones et al. 1983, 12-Klein et al. 1983, 13-Lund-Johansen & 
Omvik 1983, 14-Lund-Johansen et al. 1992, 15-Mayer et al. 1991, 16-0mvik et al. 1988, 17-
Taylor et al. 1982. 
Abbreviations: BP,es1=systolic and diastolic blood pressure at rest, HR,est=heart rate at rest, 
BPmxex= systolic blood pressure at maximal exercise, HRmxex=maximal heart rate, BPsubmx= 
systolic and diastolic blood pressure during submaximal exercise, HRsubmx=heart rate during 
submaximal exercise. 
Administration of dihydropyridine derivatives results in a reduction in systolic 
and diastolic BP at rest and during submaximal and maximal exercise in 
individuals with hypertension (Ashmore et al. 1990; Cantor & Cristal 1990; 
Fariello et al. 1989; Franz & Wiewel 1984; Gould et al. 1982; Jones et al. 1983; 
Lund-Johansen & Omvik 1983; Lund-Johansen et al. 1992; Omvik et al. 1988; 
Taylor et al. 1982). However, some authors have reported a decrease in 
diastolic BP but not in systolic BP during submaximal exercise following 
nifedipine and isradipine administration despite normalisation of resting 
diastolic and systolic BP (Halperin et al. 1993; Klein et al. 1983; Mayer et al. 
1991 ). In hypertensive subjects, HR at rest and during exercise is unchanged 
following ingestion of dihydropyridine derivatives (Cantor & Cristal 1990; 
Fariello et al. 1989; Franz & Wiewel 1984; Gillies et al. 1996; Gould et al. 1982; 
Halperin et al. 1993; Jones et al. 1983; Klein et al. 1983; Lund-Johansen & 
Omvik 1983; Lund-Johansen et al. 1992; Omvik et al. 1988; Taylor et al. 1982). 
The haemodynamic response to isometric hand grip exercise has been 
examined in hypertensive subjects following ingestion of nicardipine and 
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isradipine. Most studies have found that the effect of these agents on systolic 
and diastolic BP during isometric exercise is similar to that found for isotonic 
exercise. The exercise associated increase in systolic and diastolic BP during 
the isometric contraction was unaltered following drug administration, but BP 
during isometric exercise was lower due to lower resting BP (Dvorak et al. 
1991; Fariello et al. 1989; Taylor et al. 1982). Cantor & Cristal (1990) reported 
no change in systolic BP with isometric handgrip exercise, although diastolic 
BP was reduced resulting in reduced mean arterial pressure. HR during 
isometric handgrip exercise was unaltered by isradipine treatment (Cantor & 
Cristal 1990). 
The results of invasive haemodynamic investigations in hypertensive patients 
at rest and during submaximal exercise after administration of dihydropyridine 
derivatives are shown in Table 2.3. These agents reduce TPR at rest and 
during exercise (Klein et al. 1983; Lund-Johansen & Omvik 1983; Lund-
Johansen et al. 1992). In contrast, Gillies et al. (1996), using indirect 
techniques, found that TPR was unaltered following amlodipine administration. 
Most studies demonstrate that SVI and Cl at rest are unaltered by 
dihydropyridine derivatives in hypertensive subjects (Klein et al. 1983; Lund-
Johansen & Omvik 1983; Omvik et al. 1988). Reports of the effects on SVI and 
Cl during submaximal exercise are conflicting. 
Submaximal oxygen consumption at any given workload is unchanged 
following nifedipine, amlodipine or nisoldipine administration to hypertensive 
patients (Gillies et al. 1996; Lund-Johansen & Omvik 1983; Omvik et al. 1988). 
Similarly, Vi and RER during submaximal and maximal exercise are unaltered 
following amlodipine ingestion in hypertensive subjects (Gillies et al. 1996). 
Klein et al. (1983) reported that plasma noradrenaline concentration at rest was 
increased after 8 weeks of nifedipine therapy administered to hypertensive 
patients, but concentrations during exercise were unchanged. In contrast, 
Halperin et al. (1993) reported that long term nifedipine ingestion resulted in 
increased noradrenaline concentrations at maximal exercise but not at rest. 
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Both authors concluded that raised noradrenaline concentration was evidence 
for reflex action of the sympathetic nervous system resulting from nifedipine 
therapy, despite lack of increase in HR. 
Gillies et al. (1996) reported that plasma glucose, lactate and free fatty acid 
concentrations during submaximal exercise and blood lactate concentrations at 
maximal exercise were unaltered following ingestion of amlodipine by 
hypertensive patients. 
Thus, it appears that the dihydropyridine derivatives do not affect maximal 
exercise performance in sedentary or physically active patients with 
hypertension (Ashmore et al. 1990; Fariello et al. 1991; Gillies et al. 1996; 
Gosse et al. 1992; Halperin et al. 1993). Similarly, submaximal exercise 
performance is unaltered following amlodipine administration in physically 
active patients with hypertension (Gillies et al. 1996). Most reports have found 
that dihydropyridine derivatives ingested by hypertensive subjects lead to a 
reduction in systolic and diastolic BP during exercise, although in some studies 
only diastolic BP is reduced and not systolic BP. The majority of studies have 
indicated that, in hypertensive subjects, HR at rest and during exercise is 
unaltered following administration of these agents. Most studies have found 
that TPR at rest and during submaximal exercise is reduced after ingestion of 
dihydropyridine derivatives in hypertensive individuals; however the effects on 
Cl and SVI are conflicting. 
2.4 Summary and Discussion 
The available evidence indicates that ingestion of verapamil and diltiazem have 
no effect on maximal or submaximal exercise performance in normotensive or 
in hypertensive subjects (Ashmore et al. 1990; Cody et al. 1986; Derman et al. 
1991 b; Gordon et al. 1986; Halperin et al 1993; Herbertsson & Fagher 1990; 
Kelemen et al. 1989; Mooy et al. 1987; Myburgh & Gordon 1987; Petri et al. 
1986; Pool et al. 1985; Szlachcic et al. 1987; Vanhees et al. 1988; Yamakado 
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et al. 1983). However, the number of investigations examining the effect of 
these agents on submaximal exercise performance in hypertensive patients is 
small. 
Nifedipine however, has been consistently shown to reduce maximal exercise 
performance in normotensive subjects (Andersen & Vik-mo 1984; Chick et al. 
1986; Derman et al. 1992; Duffey et al. 1984; Gordon et al. 1986, 1987). In 
contrast, studies on hypertensive subjects have failed to demonstrate any 
effect of nifedipine or other dihydropyridine derivative on maximal exercise 
performance (Ashmore et al. 1990; Fariello et al. 1991; Gillies et al. 1996; 
Gosse et al. 1992, Halperin et al. 1993). The studies conducted on 
normotensive subjects differ to those conducted on hypertensive subjects in 
that studies using normotensive subjects involved a younger population who 
had higher values of V02max than studies of hypertensive subjects (V02max 
range from 40 to 55 ml02/kg/min for normotensive subjects and from 24 to 34 
mlOikg/min, where stated, for hypertensive subjects).The study by Gillies et al. 
(1996) involved recreational athletes; however these subjects had a mean 
V02max of only 34 mlOikg/min which is lower than the mean V02max for any 
of the studies with normotensive subjects. The fatiguing effect of B-blockers 
has been shown to be greater in individuals with high values of V02max than 
those with low values of V02max (Joyner et al. 1986; Van Baak et al. 1988). If 
dihydropyridine derivatives also have a fatiguing effect which is greatest in 
individuals with high values of V02max, then it is possible that the difference in 
V02max between the studies on normotensive and hypertensive subjects 
explains the difference in the observed effect on maximal exercise 
performance. Further investigation on the effects of dihydropyridine treatment 
on exercise performance in hypertensive subjects with higher V02max values 
are required. 
Alternatively, it is possible that dihydropyridine derivatives effect a reduction in 
exercise capacity in normotensive but not hypertensive individuals. Calcium 
channel antagonists reverse an increase in peripheral vasoconstriction in 
hypertensive subjects (Cody 1987; Omvik & Lund-Johansen 1988), but cause 
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vasodilatation in normotensive subjects. A feasible explanation is that, in 
normotensive subjects ingesting dihydropyridine derivatives, vasodilatation 
results in impaired maximal exercise capacity; whereas, in hypertensive 
patients ingesting these agents, there is no vasodilatation and therefore no 
impairment in maximal exercise capacity. 
The finding that verapamil and diltiazem administration does not affect maximal 
exercise capacity (Derman et al. 1991 b; Gordon et al. 1986; Petri et al. 1986; 
Vanhees et al. 1988), but that nifedipine does cause some attenuation of 
maximal exercise performance in normotensive subjects is a consistent 
conclusion (Andersen & Vik-mo 1984; Chick et al. 1986; Derman et al. 1992; 
Duffey et al. 1984; Gordon et al. 1986, 1987). This observed difference 
between the effects of verapamil/diltiazem and nifedipine is not likely to be due 
to differences in study design as it was also found in one study where 
verapamil was compared to nifedipine (Gordon et al. 1986). The authors of the 
relevant studies speculate that the decline in exercise performance after 
nifedipine ingestion in normotensive subjects is due to peripheral 
vasodilatation. This could lead to changes in blood flow distribution with a fall in 
blood flow to the exercising muscles. This could potentially result in decreased 
oxygen supply to the active muscle or in an impairment of the removal of 
skeletal muscle metabolites. Reduced blood flow and oxygen delivery to the 
active muscle is likely to lead to an increase in blood lactate concentration 
during exercise. Some authors have reported that nifedipine administration in 
normotensive subjects results in increased blood lactate concentration during 
exercise (Chick et al. 1986; Raffestin et al. 1985); however others have 
reported that there is no alteration in blood lactate concentration (Derman et al. 
1992; Kindermann 1987). However, blood lactate concentration during exercise 
is not altered after verapamil or diltiazem administration in either normotensive 
or hypertensive subjects (Derman et al. 1992; 1991 b; Gordon et al. 1986; Petri 
et al. 1986; Stein et al. 1984; Vanhees et al. 1988; Van Baak et al. 1987b). 
These findings of different effects on blood lactate concentration during 
exercise between verapamil/diltiazem and nifedipine support the hypothesis 
that nifedipine impairs maximal exercise performance in normotensive subjects 
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by reducing blood flow to the active skeletal muscle and thereby increasing 
blood lactate concentration. As verapamil and diltiazem have lesser effect on 
the vasculature than nifedipine (Man in't Veld 1989), this postulate is consistent 
with the observed greater effect of nifedipine than verapamil or diltiazem on 
maximal exercise performance. 
As nifedipine is known to have fewer negative inotropic and chronotropic 
effects than verapamil (Kaplan 1989; Man in't Veld 1989), the fact that maximal 
exercise performance in normotensive subjects is reduced by nifedipine and 
not verapamil, implies that it is not central cardiovascular effects which cause 
the reduction in maximal exercise capacity following nifedipine administration. 
Verapamil does not impair maximal exercise capacity; therefore, any reduction 
in cardiac function due to the negative effects of verapamil is not sufficient to 
limit exercise capacity. In addition, Ashmore et al. (1990) reported that 
verapamil (but not nifedipine) ingestion for a 3 week period by hypertensive 
patients impaired left ventricular peak emptying and filling rates during a 
maximal exercise test. However, maximal exercise capacity was unchanged. 
This is further evidence against the hypothesis that changes in central 
cardiovascular function due to anti-hypertensive agents result in reduction of 
exercise capacity. 
Nifedipine causes greater peripheral vascular dilatation than verapamil, 
resulting in, at least in the short term, greater reflex sympathetic stimulation 
(Agabiti-Rosei et al. 1986; Kaplan 1989; Man in't Veld 1989). There is some 
speculation that long term administration of calcium channel blockers results in 
a blunting of the physiological response to sympathetic stimulation (Yamakado 
et al. 1983). This would explain why the reflex tachycardia seen with the 
dihydropyridine derivatives usually subsides over time despite high serum 
concentrations of noradrenaline (Klein et al. 1983). As exercise is a state of 
high sympathetic flux, an attenuated physiological response to sympathetic 
stimulation could possibly explain the observed impairment of exercise 
performance following nifedipine ingestion. Alternatively, nifedipine could be 
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acting peripherally at the level of the skeletal muscle to impair contractility. 
These areas warrant further investigation. 
There is no evidence that hormone secretion, at rest or during exercise, is 
inhibited by calcium channel antagonism (Kindermann 1987; Raffestin et al. 
1985; Stein et al. 1984); therefore the impairment of maximal exercise 
performance following nifedipine ingestion in healthy subjects is not due to 
reduced hormone secretion during exercise. 
Few studies have investigated the effects of dihydropyridine derivatives on 
submaximal exercise performance. Gillies et al. (1996) found no effect of 
amlodipine on submaximal exercise endurance in physically active 
hypertensive patients. Although the subjects in this study were all recreational 
athletes, their mean V02max was relatively low at 34 ml02/kg/min. Further 
research into the effects of dihydropyridine derivatives on submaximal exercise 
performance in physically active subjects with hypertension is needed. This is 
important, as it is precisely submaximal exercise which physically active 
patients taking anti-hypertensive medication perform. Further, differences 
between medications that are not evident during maximal exercise testing may 
become apparent with submaximal exercise testing (Mclenachan et al. 1991 ). 
Furthermore, it is not known if calcium channel antagonism alters the 
physiological adaptations (including a beneficial effect on hypertension) to 
exercise training in hypertensive patients. Further investigation is needed in 
order to clarify these issues so that accurate advice can be given to active 
hypertensive patients regarding their anti-hypertensive medication. 
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Chapter 3. Literature review - The effects of beta-receptor 
antagonists on exercise performance and comparison with the 
effects of calcium channel antagonists. 
3.1 Introduction 
The effects of p-receptor antagonists on exercise performance and the 
physiological response to exercise have been fully reviewed recently by several 
authors (Gordon & Duncan 1991; Kaiser 1984; Tesch 1985; Van Baak 1988). 
This review will not attempt to re-evaluate all the results in the literature. It will 
merely present the key findings which are of specific relevance to this thesis 
and compare these to the effects of calcium channel antagonists outlined in 
the previous chapter. 
3.2 Exercise performance 
3.2.1 Maximal exercise performance 
Most studies on normotensive subjects have indicated that measures of 
maximum exercise capacity including V02max, Wlmax and exercise test 
duration are reduced by administration of p-antagonists (Ades et al. 1984; 
Gullestad et al. 1989a, 1991; Kullmer et al. 1987; Van Baak 1988; Van Bortel & 
Van Baak 1992). This finding is in contrast to the reports on verapamil and 
diltiazem in normotensive subjects where there is no effect on maximal 
exercise capacity following ingestion of these agents (Derman et al. 1991 b; 
Gordon et al. 1986; Petri et al. 1986; Vanhees et al. 1988). Some attenuation 
of maximal exercise capacity is reported after nifedipine ingestion in 
normotensive subjects. However, in studies where nifedipine is compared to a 
P-blocker, the reduction in maximal exercise capacity seen with nifedipine is 
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not as great as that reported with the P-blocker (Derman et al. 1992; Gordon et 
al. 1986). 
Some studies report a similar reduction in maximal exercise capacity following 
P-blockade in hypertensive subjects to that seen in normotensive subjects 
(Gordon et al. 1988, Kaiser et al. 1985, Thompson et al. 1989). However, in 
other studies no impairment in maximal exercise performance is reported 
(Leenen et al. 1980; Luurila et al. 1987; Reybrouck et al. 1977). This 
discrepancy might be explained by differences in physical activity status of the 
subjects. Most studies which have examined the effect of p-blockade on 
trained subjects (whether hypertensive or normotensive), have found that P-
blockers clearly decrease maximal exercise performance (Anderson et al. 
1985; Derman et al. 1992; Thompson et al. 1989). However, many studies 
using sedentary subjects have reported that maximal exercise performance is 
not altered following P-blocker ingestion (Franciosa et al. 1980; Reybrouck et 
al. 1977; Violante et al. 1984). Van Baak et al. (1988) investigated the effects 
of P-antagonists on maximal exercise performance in hypertensive patients 
and normotensive controls matched for V02max, and found a similar reduction 
in V02max and Wlmax in both groups. These findings indicate that it is the 
physical activity status of the subjects, and not the presence of hypertension, 
which determines the effect of p-blockade on their maximal exercise capability. 
In concurrence with this finding, Joyner et al. (1986) found that P-blockers 
reduce maximal exercise capacity to a greater extent in trained men compared 
with untrained men. 
Studies investigating the effect of calcium channel antagonists on maximal 
exercise -performance in hypertensive subjects have failed to demonstrate any 
impairment. However, these studies investigated subjects with low values of 
V02max and hence, it is possible that, as for P-blockers, a reduction in 
maximal exercise capacity may be evident only in trained subjects with high 
values of V02max. 
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3.2.2 Submaximal exercise performance 
The time to exhaustion during prolonged submaximal exercise is reduced by 
up to 50% following the ingestion of p-blocking agents (Lundborg et al. 1981; 
Van Baak 1988; Van Bortel et al. 1991; Vanhees et al. 1988). The impairment 
in prolonged exercise endurance occurs in both normotensive and 
hypertensive subjects. It occurs to a greater extent with non-selective P-
blockade than with P1-selective blockers (Anderson et al. 1985). 
Whilst the effect of p-blockade on submaximal exercise capacity has been 
extensively investigated, the same studies have not been performed using 
calcium channel antagonists. The available studies report that there is no 
impairment in submaximal exercise endurance after verapamil or diltiazem 
ingestion in normotensive or hypertensive subjects (Derman et al. 1991 b; 
Herbertsson & Fagher 1990; Mooy et al. 1987; Vanhees et al. 1988). However, 
the number of studies is small. In normotensive subjects, any impairment in 
submaximal exercise capacity after the ingestion of dihydropyridine derivatives 
is less than that seen with p-blockade (Derman et al. 1992; Kindermann 1987). 
Submaximal exercise performance in hypertensive subjects after 
dihydropyridine administration has not been studied. 
3.3 Physiological effects of exercise 
3.3.1 Central haemodynamics 
Beta-blockers reduce HR and systolic and diastolic BP at rest and during 
exercise. The reduction in HR is partially compensated for by an increase in 
stroke volume both at rest and during exercise (Frisk-Holmberg et al. 1985; 
Scruggs et al. 1991 ), so that the reduction in cardiac output is less pronounced 
than the HR reduction (Van Baak 1988). Most studies have demonstrated a 
reduction in cardiac output during p-blockade at rest and during maximal and 
submaximal exercise of 5-15% (Bonelli et al. 1977; Freund et al. 1987; Van 
Baak 1988). 
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submaximal exercise of 5-15% (Bonelli et al. 1977; Freund et al. 1987; Van 
Baak 1988). 
In contrast to P-blockers, calcium channel antagonists do not reduce cardiac 
output at rest (Klein et al. 1983; Lund-Johansen et al. 1992, Omvik et al. 1988). 
Also, most studies show that, in hypertensive subjects, cardiac output during 
exercise is either unchanged or increased after calcium channel antagonist 
administration (Gillies et al. 1996; Klein et al. 1983; Lund-Johansen et al. 1992; 
Omvik & Lund-Johansen 1988). 
The reduction in cardiac output after administration of P-blockers has been the 
traditional explanation for the reduction in exercise performance found 
following ingestion of these agents. However, there are several findings which 
do not concur with this hypothesis. Firstly, P-blockers with intrinsic 
sympathomimetic activity do not decrease cardiac output as much as other P-
blockers (Ades et al. 1989), but result in the same degree of premature fatigue 
(Duncan et al. 1990; Kullmer et al. 1987). Secondly, agents which result in the 
same degree of reduction in resting and exercising heart rate produce different 
degrees of impairment of maximal exercise performance (Lundborg et al. 
1981 ). Thirdly, other anti-hypertensive agents reduce resting and exercise BP 
without affecting exercise performance (Myburgh & Gordon 1987; Petri et al. 
1986). Thus, there is considerable evidence to indicate that it is not the 
changes in central haemodynamics produced by P-blockade that result in 
impairment of exercise performance. 
3.3.2 Peripheral haemodynamics 
Beta-adrenergic receptors are found in skeletal muscle vasculature and hence 
P-blockade would be expected to lead to vasoconstriction of these vessels and 
consequently reduction of skeletal muscle blood flow. Several studies have 
shown this to occur (Freund et al. 1987; Mcsorley & Warren 1978). However, 
other studies have measured leg oxygen uptake and found that while blood 
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flow to the leg was reduced by 10% during submaximal exercise, the arterio-
venous oxygen difference was increased so that leg oxygen uptake was 
unchanged (Frisk-Holmberg et al. 1985; Trapp-Jensen et al. 1976). Thus, it 
appears that any interference with blood flow to the working muscle caused by 
~-blockade does not result in a diminished oxygen uptake by the muscle. 
However, it may result in a decreased rate of removal of muscle metabolites. 
3.3.3 Ventilation and gaseous exchange 
There have been some reports of changes in ventilatory parameters during 
exercise after ingestion of ~-blockers (Joyner et al. 1987; Mcleod et al. 1985). 
However, these changes in ventilation are small (Pearson et al. 1987) and are 
unlikely to cause the decreased exercise performance produced by these 
agents. 
Most studies have not demonstrated any effect of calcium channel antagonism 
on ventilatory parameters during maximal or submaximal exercise in 
hypertensive or normotensive subjects (Chick et al. 1986; Derman et al. 1991 b, 
1992; Gordon et al. 1986, 1987; Kindermann 1987; Petri et al. 1986; Raffestin 
et al. 1985; Stein et al. 1984; Van Baak et al. 1987b). 
3.3.4 Carbohydrate metabolism 
Skeletal muscle and blood lactate concentrations during exercise are the result 
of a complex interaction between release of lactate into the blood stream by 
exercising and non-exercising muscle, the hepatic uptake of lactate for 
conversion to blood glucose, the use of lactate as a fuel source by exercising 
muscle and the lactate distribution volume (Stanley et al. 1985). Muscle lactate 
concentrations have been reported to be unchanged (Broberg et al. 1988; 
Frisk-Holmberg et al. 1979; Lausitiola et al. 1983) or decreased (Lundborg et 
al. 1981) during exercise with ~-blockade. Similarly, reports of blood lactate 
concentrations during submaximal and high intensity exercise after ~-blockade 
are inconsistent (Van Baak 1988). These discrepancies suggest that any effect 
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of P-blockers on lactate kinetics is probably small, and is unlikely to explain the 
reduction in exercise performance seen with P-blockade. 
Some studies have shown a reduction in blood glucose concentrations with P-
blockade during high intensity exercise (Van Baak 1988) or prolonged 
submaximal exercise (Lundborg et al. 1981, Wijnen et al. 1993). However, 
other studies have not found lower blood glucose concentrations during either 
maximal or submaximal exercise after P-blockade, even though exercise 
performance was impaired (Gullestad et al. 1989b, 1991; Lausitiola et al. 1983; 
Van Baak et al. 1993). These findings demonstrate that hypoglycaemia is 
probably not a cause of the premature fatigue during exercise experienced 
after P-blockade in these studies. 
3.3.5 Fat metabolism 
Beta-adrenoreceptors are found in adipose tissue and their stimulation results 
in lipolysis. P-blockers reduce the plasma concentration of free fatty acids 
during exercise (Frisk-Holmberg et al. 1985; Lausitiola et al. 1983; Lundborg et 
al. 1981; Van Baak et al. 1987a; Verstappen & Van Baak 1987), although 
some authors report that P-blockade decreases plasma free fatty acid 
concentration only after exercise (Cosenzi et al. 1995; Wijnen et al. 1993). As 
the uptake of free fatty acids by skeletal muscle depends on the plasma 
concentration (Ahlborg et al. 1974), the exercising muscle will take up less fatty 
acid than normal after P-blockade. This is likely to cause a shift from fat to 
carbohydrate oxidation by the active skeletal muscle (Wijnen et al. 1993) and 
there is some evidence that liver glycogenolysis (and not muscle 
glycogenolysis) is accelerated during exercise after P-blockade (Ahlborg & 
Juhlin-Dannfelt 1994). This is a possible cause of premature fatigue during 
prolonged exercise. However, Van Baak et al. (1993) infused triglycerides 
during submaximal exercise in subjects ingesting either P-blockers or placebo. 
Premature fatigue occurred after p-blockade despite raised plasma free fatty 
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acid concentrations. Thus inhibition of adipose lipolysis is an improbable cause 
of the reduced endurance seen during ~-blockade. 
The plasma concentration of free fatty acids, glycerol and triglycerides during 
exercise are unchanged by verapamil or diltiazem in hypertensive or 
normotensive subjects (Derman 1993; Petri et al. 1986) suggesting that 
lipolysis is unaltered by these agents. However, nifedipine increases the 
concentration of free fatty acids and ketones in the plasma during exercise in 
normotensive subjects (Raffestin et al. 1985). Together with the increase in 
blood glucose and lactate concentrations reported in this study, this is evidence 
that there is an increased rate of glycogenolysis and lipolysis as a result of 
increased sympathetic stimulation in normotensive subjects. This may subside 
with time. Gillies et al. (1996) found no alteration in plasma glucose, lactate or 
free fatty acid concentrations during submaximal exercise following amlodipine 
ingestion for 2 weeks by hypertensive patients. 
3.3.6 Serum potassium concentrations 
The stimulation of ~-receptors associated with the membrane Na+K+-ATPase 
in muscle cells promotes the uptake of potassium into the cell (Van Baak 
1988). ~-blockers increase serum potassium during both maximal and 
submaximal exercise and during recovery (Gullestad et al. 1989b; Leenen et 
al. 1980; Lundborg et al. 1981; Schneider et al. 1994; Van Baak et al. 1987a). 
As very high serum potassium concentrations (above 5-6 mmol/1) are known to 
impair skeletal muscle contraction (Jones 1981 ), the raised potassium levels 
seen with ~-blockade are a plausible cause of reduced exercise performance. 
Further, non-selective ~-blockade results in a higher potassium concentration 
during exercise than ~1-selective blockade (Gullestad et al. 1989b, 1991 ), and 
exercise performance is reduced to greater degree following non-selective than 
selective ~-blockade (Anderson et al. 1985). 
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However, there is evidence to suggest that the reduced exercise capacity seen 
with p-blockade is not attributable to increased serum potassium concentration. 
Gullestad et al. (1991) reported that the non-selective P- blocker, propranolol, 
reduced maximal exercise capacity and increased serum potassium 
concentration during exercise; however, selective antagonism of P2-receptors 
reduced maximal exercise performance but did not alter serum potassium 
concentration during exercise. Derman (1993) found that serum potassium 
concentration was not different in those subjects who experienced premature 
fatigue during prolonged submaximal exercise from those subjects who did not 
fatigue prematurely. McKelvie & Jones (1991) reported that while serum 
potassium was raised to the same concentration by both high and low dose P-
blockade, maximal exercise capacity was reduced only by the high dose P-
blockade. These findings demonstrate a dissociation between raised serum 
potassium concentration and impaired exercise performance and indicate that 
the reduction in exercise performance following P-blockade is not a result of an 
increase in serum potassium concentration. 
Serum potassium concentration during exercise in normotensive subjects are 
not altered after the administration of verapamil or diltiazem (Derman 1993; 
Stein et al. 1984). The effects of verapamil or diltiazem on serum potassium 
concentration in hypertensive subjects, or the effects of dihydropyridine 
derivatives have not been reported. 
3.3. 7 Hormone concentrations 
Beta-blockers have no effect on the concentration of most hormones at rest but 
hormonal levels during exercise are markedly altered (Gullestad et al. 1989a). 
The normal increase in plasma adrenaline concentrations seen with exercise is 
substantially accentuated by P-blockade (Cleroux et al. 1987; Gullestad et al. 
1989a). The normal increase in plasma noradrenaline concentration is 
unaltered during submaximal exercise (Cleroux et al. 1987; Lundborg et al. 
1981) or is slightly increased (Gullestad et al. 1989a). Plasma concentrations 
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of growth hormone, prolactin and cortisol during submaximal exercise are 
increased after P-blockade, while plasma dopamine concentration is 
unchanged (Gullestad et al. 1989a). The physiological increase in plasma renin 
concentration during exercise is attenuated (Bonelli et al. 1977; Gullestad et al. 
1989a) following P-blockade. Gullestad et al. (1989a) reported that there was 
no correlation between the perception of fatigue and plasma adrenaline, 
noradrenaline, growth hormone, prolactin, cortisol or renin concentrations. 
Ratings of perceived exertion during submaximal exercise were higher after 
non-selective than P1-selective blockade, but there were no differences in 
hormone concentrations between non-selective and P1-selective blockade. This 
finding suggests that the increased perception of fatigue seen with P-blockers 
is not associated with altered plasma hormone concentrations during exercise. 
3.3.8 Skeletal muscle contractile dysfunction 
Most studies which have examined the effect of P-blockers on skeletal muscle 
power output during high intensity exercise of short duration report no effect of 
P-blockade on the ability to generate power (Derman et al. 1993; Rusko et al. 
1980; Yoroko et al. 1990), although others have found that P-blockade reduces 
power output (Kaiser 1984). 
Cupido et al. (1994) reported that the torque achieved by a maximum voluntary 
contraction of the quadriceps muscle and electromyographic activity of the 
muscle after a 4 minute fatigue protocol, consisting of intermittent voluntary 
isometric contractions of the quadriceps, were unaltered following P-blockade. 
However, two authors have reported that when short term, high intensity 
exercise was tested immediately following the completion of prolonged 
submaximal exercise, P-blockade resulted in a decrease in mean muscle 
power output in subjects who fatigued prematurely during the prolonged 
exercise (Derman et al. 1991 a; Karlsson et al. 1983). The reduction in muscle 
power output did not occur before the bout of prolonged submaximal exercise 
had commenced. This suggests that P-blockade induces fatigue of skeletal 
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muscle during exercise. Further, Derman et al. (1991 a) found that in those 
subjects who fatigued prematurely during prolonged submaximal exercise after 
P-blockade, integrated electromyographic activity was increased during the 
preceding 1 O minutes prior to exhaustion, suggesting increased recruitment of 
muscle fibres perhaps in response to impaired skeletal muscle function. 
Hence, it is possible that P-receptor antagonists reduce exercise performance 
by inducing early fatigue of the active skeletal muscle. This is consistent with 
the hypothesis that it is skeletal muscle contractility and not cardiovascular 
function which determines the quality of exercise performance (Noakes 1988). 
Recent evidence suggests that protein oxidation is increased following P-
blockade both at rest (Lamont 1995) and during exercise (Lamont et al. 1995). 
In addition, Powers et al. (1995) reported that P-blockers administered to rats 
during an exercise training program reduced the training induced increase in 
skeletal muscle oxidative capacity compared to rats undergoing an exercise 
training program without P-blockade. It is possible that these effects of P-
blockade on muscle protein and oxidative capacity may influence skeletal 
muscle contractility or cause premature fatigue. 
In contrast to the above findings on the effects of P-blockade on skeletal 
muscle function, Gillies et al. (1996) reported that ingestion of the 
dihydropyridine derivative, amlodipine, did not alter skeletal muscle function 
either before or after prolonged submaximal exercise in hypertensive patients. 
Skeletal muscle function was tested by measuring the torque achieved by 
maximum voluntary isometric contractions of the quadriceps muscle, and 
recording the time taken before the subject was unable to maintain a torque 
equal to 70% of the initial torque during repeated maximum contractions. This 
finding suggests that skeletal muscle function is unaltered by dihydropyridine 
derivative ingestion. Prolonged submaximal exercise endurance was also 
unaltered by amlodipine ingestion in this study, which contrasts with the effect 
of P-blockade in the studies where impaired skeletal muscle function was found 
after prolonged submaximal exercise (Derman et al. 1991 a; Karlsson et al. 
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1983). Thus, after amlodipine ingestion by hypertensive patients, there is no 
impairment of submaximal exercise endurance and no impairment of skeletal 
muscle function after prolonged submaximal exercise, suggesting that there is 
no premature skeletal muscle fatigue. This is consistent with the hypothesis 
that premature skeletal muscle fatigue may be the basis of impaired exercise 
performance when it occurs following anti-hypertensive medication 
administration. 
3.4 Conclusions 
The influence of ~-blockade and calcium channel antagonism on exercise 
performance and the physiological response to exercise are summarised in 
Tables 3.1 and 3.2. 
While ~-blockers and calcium channel antagonists both act to reduce systolic 
and diastolic BP during rest and exercise in individuals with hypertension, 
these agents act via different pathways. Consequently, they have different 
effects on the physiological response to exercise and this may lead to different 
effects on exercise performance. 
Beta-blockade has been consistently shown to reduce maximal and 
submaximal exercise performance in both normotensive and hypertensive 
Table 3.1 Influence of ~-blockade and calcium channel antagonism on exercise performance and 
h the o wsioloaical resoonse to exercise. 
Maximal ex. Submax. ex. BP during HR during Cardiac Minute 
performance performance exercise exercise outout ventilation 
~-blockers r J, J, J, J, J,, H 
Verapamil H H .J/,H* j,# H, i# H 
Diltiazem 
Nifedipine J,•,H# ? J,#, H* H# H, i# H 
. # Physically active subjects, Normotens1ve subjects, Hypertensive subjects 
Abbreviations: !=decreased, i =increased, H=unaltered, ?=unknown, ex.=exercise, submx.=submaximal, 
BP=systolic and diastolic blood pressure, HR=heart rate. 
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Table 3.2 Influence of ~-blockade and calcium channel antagonism on serum metabolite 
tr dkltt 1ft' concen ra ions an s e e a muse e a 1que. 
Concentrations Blood Blood Serum free Serum Serum Skeletal 
durina exercise lactate alucose fattv acids potassium hormones muscle fatiaue 
~-blockers H,.J,,f .J,,H .j, i Manyi i 
Somet-t 
Verapamil H H H • ?# H,. H ? 
Diltiazem 
Nifedipine i•, ?# f•, H*, ?# i·. ?# ? Many i ? 
Somet-t . . Physically active sub1ects, Normotens1ve subJects, Hypertensive sub1ects . 
Abbreviations: t=decreased, i =increased, t-t=unaltered, ?=unknown. 
subjects (Van Baak 1988). Calcium channel antagonism has been shown to, at 
most, have lesser effects on exercise performance than p-blockade, although 
the effects of calcium channel antagonists have not been extensively 
investigated. 
Beta-blockers reduce cardiac output during rest and exercise whilst calcium 
channel antagonists maintain cardiac output. However, there is evidence to 
show that it is not the reduction in cardiac output seen with p-blockers results in 
the reduction in exercise performance. Blood flow to active skeletal muscle 
may be reduced during exercise with either p-blockade or calcium channel 
antagonism: with P-blockade this does not reduce the oxygen supply to the 
working muscle but may interfere with the removal of muscle metabolites. 
Beta-blockade results in small changes to ventilatory parameters during 
exercise but these are unlikely to lead to a reduction in exercise performance. 
Calcium channel antagonism does not alter ventilation during exercise. 
Both p-blocker and calcium channel antagonist ingestion results in small 
changes in blood lactate concentrations during exercise but these findings are 
inconsistent and so are unlikely to lead to significant changes in exercise 
performance. A reduction in blood glucose during exercise is sometimes 
reported after P-blockade, but this is not always seen even in the presence of 
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an impairment of exercise performance. Nifedipine, but not verapamil or 
diltiazem, results in increased blood glucose concentrations during exercise in 
normotensive subjects and this has been attributed to an increase in 
sympathetic stimulation secondary to vasodilatation. 
The concentration of serum free fatty acids during and after exercise is 
reduced after P-blockade, but there is evidence that this does not cause the 
impairment in exercise performance seen after P-blockade. Nifedipine, but not 
verapamil or diltiazem, results in an increase in serum free fatty acid 
concentration during exercise. This is thought to be due to increased lipolysis 
as a result of increased sympathetic stimulation. 
Beta-blockade results in increased serum potassium concentration due to 
decreased uptake of potassium into muscle cells; however there is evidence 
that the reduction in exercise performance following P-blockade is not due to 
the increased serum potassium concentration. 
Beta-blockade results in increases in the concentrations of many hormones 
during exercise but this does not correlate with the reduction in exercise 
performance. Verapamil and diltiazem do not alter noradrenaline or growth 
hormone concentrations during exercise but nifedipine increases these in 
normotensive subjects. The increase in hormone concentration seen with 
nifedipine is different from that seen with the p-blockers, in that nifedipine 
raises noradrenaline concentration and not adrenaline concentration, while the 
reverse is true with P-blockade. The increase in hormone concentrations seen 
after nifedipine administration is thought to be due to increased sympathetic 
stimulation. It is not known whether the increased sympathetic stimulation is 
sustained over long periods of administration of nifedipine. 
It is possible that P-blockade results in premature fatigue of skeletal muscle 
fibres either via an increase in skeletal muscle protein oxidation, a reduction in 
skeletal muscle oxidative capacity, a direct influence on the skeletal muscle 
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fibre or a combination of several of the effects on exercise physiology 
discussed above. It appears that amlodipine does not alter skeletal muscle 
function in hypertensive subjects (Gillies et al. 1996). The effects of other 
calcium channel antagonists on skeletal muscle function have not been 
reported. 
The evidence for increased sympathetic stimulation after nifedipine ingestion 
by normotensive subjects has been reported as documented above. This does 
not occur after verapamil or diltiazem ingestion in either normotensive or 
hypertensive subjects. Bearing in mind the lack of comprehensive research into 
the effects of calcium channel antagonists on exercise performance, the only 
evidence of impairment of exercise performance seen after calcium channel 
antagonist administration is seen after nifedipine ingestion by normotensive 
subjects. However, it is not known whether the increase in sympathetic 
stimulation is causally related to the impairment in maximal exercise 
performance. This differs from the situation seen with B-blockade where the 
sympathetic system is blocked from exerting its complete action. 
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Chapter 4. General methodology. 
The general methodology common to the different studies in Chapters 5-8 is 
described in this chapter. Methodology specific to any particular chapter is 
outlined in that chapter. 
All studies described in this thesis were approved by the South African 
Medicines Control Council and the Ethics and Research Committee of the 
Faculty of Medicine at the University of Cape Town. 
4.1 Anti-hypertensive drugs 
lsradipine is a calcium channel blocker of the 1,4-dihydropyridine group. It acts 
primarily as a vasodilator with minimal negative inotropic effects 
(Chellingsworth et al. 1988). Several multicentre clinical trials have shown that 
isradipine has greater efficacy in reducing blood pressure than propranolol, 
hydrochlorothiazide, prazosin and diltiazem (Dahlof 1989; Vermeulen et al. 
1988). It has a dose dependent effect for the reduction of blood pressure (up to 
5 to 7.5 mg twice daily) and for the presence of side effects (Dahlof 1989). At a 
dose of 2.5 mg twice daily, isradipine results in blood pressure reduction of 
approximately 80% of the maximum and an incidence of side effects which is 
not different to that of placebo (Kirch et al. 1990; Simonsen & Sundstedt 1989). 
The most common side effects are headache, palpitations, dizziness, flushing 
and oedema. These side effects often disappear if therapy is continued for 
several weeks (Dahlof 1989). It does not have adverse metabolic effects, there 
is no associated tachycardia, fluid retention or orthostatic hypotension and 
renal function is preserved (Dahlof 1989). lsradipine has a long duration of 
action with twice daily doses producing a sustained reduction in blood pressure 
over 12 hours (The Italian-Belgian isradipine study group 1989). 
Atenolol is a ~1-selective adrenergic receptor antagonist which is widely used in 
the treatment of hypertension, angina pectoris, cardiac arrhythmias and 
myocardial infarction. It has only very weak action at ~2-receptors and hence 
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results in little bronchoconstriction and vasoconstriction. It has no partial 
agonist activity. Atenolol has low lipid solubility and so concentrations in brain 
tissue are low; this may be the reason for the low incidence of central nervous 
system side effects compared to lipophilic ~-blockers such as propranolol. 
Atenolol is well tolerated, although in 2-3% of patients therapy must be 
withdrawn due to adverse effects. The most common side effects are cold 
extremities and fatigue (Dollery 1991 ). 
4.2 Study Overview 
The effects of two different anti-hypertensive agents, isradipine, a 
dihydropyridine calcium channel antagonist and atenolol, a ~1-selective 
adrenergic antagonist, on different aspects of exercise performance were 
compared in physically active subjects with mild to moderate essential 
hypertension. A placebo controlled, crossover study design where active drug 
treatments were randomised and double blinded, was used. Maximal, 
submaximal and short duration, high intensity exercise performance was 
assessed. 
Twelve subjects with resting diastolic blood pressure greater than 90 mmHg 
who performed vigorous recreational exercise on at least 4 occasions a week 
were recruited to participate in these studies. All subjects gave their written 
informed consent for these studies. Their descriptive characteristics were: 10 
males and 2 females, mean age 45 yrs (range 26-61 yrs), mean systolic blood 
pressure 155 mmHg (range 140-175 mmHg), mean diastolic blood pressure 
100 mmHg (range 90-108 mmHg), mean heart rate at rest 61 bpm (range 38-
73 bpm), mean V02max 37.8 ml02/min/kg (range 31.8-46.7 ml02/min/kg), 
mean weight 76 kg (range 41-90 kg), mean height 173 cm (range 140-190 cm). 
All subjects were free of any serious medical disorders other than 
hypertension, were non-smokers and not on any concurrent medication. 
Subjects were instructed to maintain a constant level of activity throughout the 
duration of the trial and to avoid any strenuous physical exercise for 36 hours 
preceding each laboratory visit. 
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An overview of the study design is given in Figure 4.1 . After a minimum period 
of 2 weeks without medication, subjects visited the laboratory on at least two 
occasions for determination of blood pressure, physical examination, ECG 
blood and urine analysis, familiarisation with the testing equipment and an 
initial incremental exercise test to exhaustion for determination of baseline 
V02max. Subjects then began the first active drug treatment period during 
which time they ingested either isradipine 2.5 mg twice daily, or atenolol 50 mg 
twice daily for 4 weeks. These dosages of isradipine and atenolol were chosen 
as they have been shown to be the standard doses used in the management of 
hypertension and to have equipotent blood pressure lowering effects 
(lsradipine in Hypertension Study Group 1989). During the fourth week of the 
drug treatment period the subjects underwent exercise testing on three 
consecutive days. On the first day of testing, a Wingate test was performed to 
measure their ability to perform short duration, high intensity exercise. On the 
second day of testing, subjects performed an incremental exercise test to 
exhaustion to assess maximal exercise capacity. On the third day, the subjects 
underwent a prolonged submaximal exercise test to measure time to 
Figure 4.1 Overview of study design. 
Visit 1 Visit2 
Screening BP measurement 
BP measurement Examination 
Familiarisation ECG 
Consent Bloods & Urine 
Maximal ex. test I Drug 1 b.d. for 4 weeks 
l 
Day 26 - Wingate test 
I Placebo b.d. for 4 weeks 
I 
Day 27 - Maximal exercise test 
Day 28 - Prolonged submaximal I 
exercise test I 
Drug 2 b.d. for 4 weeks 
f 
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exhaustion, and cardiorespiratory and metabolic parameters during prolonged 
exercise. A placebo was then ingested twice daily for a period of four weeks 
with identical exercise protocol testing performed during the fourth week. This 
was followed by the second drug treatment period where the alternate drug 
was ingested. The exercise testing protocol was repeated in the fourth week. 
Drug treatments were randomised and double blind; however the placebo 
treatment was single blind. This was done to avoid the need for washout 
periods between drug treatments, which would have increased the length of 
time during which these hypertensive patients were without active medication. 
Blood pressure and side effects were monitored regularly throughout the study. 
Subjects attended the laboratory at the same time of day on each day of 
exercise testing. They were asked to eat a standardised meal 2 to 4 hours 
before testing and to ingest their medication 3 hours prior to testing. Before 
testing started, subjects were seated in a quiet environment for a period of 15 
minutes. Resting blood pressure (seated and standing) was then measured 
and recorded twice using a calibrated mercury sphygmomanometer (Korotkoff 
phase I and IV), and the mean blood pressure in each of the seated and 
standing positions was calculated. Heart rate at rest (seated and standing) was 
measured by palpation of the radial artery. Body mass was measured on a 
Seca electronic scale. 
4.3 Exercise tests 
4.3.1 Maximal and submaximal exercise tests 
Before exercise commenced, a forearm vein was cannulated with an 18 gauge 
Jelco flexible catheter (Criticon, Tampa, Florida, USA). A 3 way stopcock 
(Discofix-3, Belgium) was attached to enable multiple blood samples to be 
taken during the tests. Blood was drawn at regular intervals throughout the 
maximal and submaximal tests and 1.0 ml added to test tubes containing 2 ml 
of 70% perchloric acid and stored in ice for blood lactate analysis. During the 
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prolonged submaximal exercise test the catheter and stopcock were flushed 
with 2.0 ml of normal saline after drawing blood to maintain patency. During 
both the maximal and submaximal tests, immediately prior to sampling, 0.5 ml 
of blood was drawn and discarded to empty the catheter of any blood or saline. 
The maximal and submaximal exercise tests were administered on a 
electromechanically braked cycle ergometer (Godart, Bilthoven, Holland). 
During these tests the subjects cycled with a model no. 2766 counterbalanced 
head support holding a model no. 2700 Rudolph valve (both by Hans Rudolph 
Inc., Kansas City, KS, USA). A clip prevented nasal breathing. Expired air was 
measured for oxygen (Ametec 0 2 Analyzer Model 3A, Theridox, Pittsburgh, 
PA, USA) and carbon dioxide content (Ametec Carbon Dioxide Analyzer Model 
CD-3A, Theridox, Pittsburgh, PA, USA). Both analysers were calibrated prior to 
testing using gases of known composition. lnspiratory volume was measured 
with a Mijnhardt dry gas meter that had been calibrated against a Collins chain-
compressed gasometer (Collins Inc., Braintree, MA, USA). Total inspiratory 
ventilation (Vi), oxygen uptake (V02), carbon dioxide production (VC02) and 
respiratory exchange ratio (RER) were calculated every 3 sec by an on-line 
microcomputer (Sperry), using software based on conventional equations as 
previously described from this laboratory (Noakes et al. 1990). The average 
value of each parameter for each minute was stored for later printing. 
Blood pressure during the maximal and submaximal exercise tests was 
measured by means of audible sphygmomanometry using the same calibrated 
mercury sphygmomanometer (Standby, WA Baum Co. Inc., New York, USA). 
Korotkoff phase I and IV were used. The systolic blood pressure was recorded 
during exercise at intensities less than approximately 80% of the subjects 
V02max. During exercise above this intensity, upper body and arm movements 
become too great to allow accurate blood pressure measurements. Heart rate 
during both the maximal and submaximal exercise tests was recorded using an 
electrocardiogram monitor (Loheimer M607, Munich, West Germany) with self-
adhering electrodes placed in the modified CMs position. 
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The subjects indicated their Borg rating of perceived exertion (APE) on a ten 
point scale during the maximal and submaximal tests (Borg 1982). 
On completion of each exercise test, the collected blood samples were 
centrifuged at 2000 rpm for 15 min in a Sigma 302-K centrifuge (Munich, 
Germany). The tubes containing 2.0 ml of 70% perchloric acid had been 
weighed on a Sartorius 1412MP*-1 scale (Gottingen, West Germany) before 
the test began and stored in a refrigerator. After centrifuging, the samples were 
again weighed to calculate the actual volume of blood collected. The 
supernatant was then decanted and frozen for later analysis. An assay 
adapted from Gutman and Wahlfeld (1974) was used to determine the lactate 
concentration of the samples. 
4.3.1.1 Maximal exercise test 
The maximal exercise test was a progressive exercise test to exhaustion. Male 
subjects began cycling at a workload of 120W and female subjects at a 
workload of 90W. The workload was increased every minute by 15W until the 
subject was unable to continue pedalling. Every minute throughout the test, 
heart rate and APE were recorded and 1 .0 ml of blood drawn for lactate 
estimation. Blood pressure was recorded every second minute. Further 
samples of blood were drawn every minute for 5 min after exercise terminated. 
The V02max and the peak Vi were taken as the highest V02 and highest Vi 
respectively recorded during any one minute period (Noakes 1988). Peak 
workload was taken as the highest workload (W) maintained for a complete 
minute during the test. Exercise time to exhaustion was calculated as the total 
time for which the subject continued cycling including the fraction of any 
uncompleted minute. 
After each maximal exercise test, 75% of the V02max was calculated. Blood 
pressure and blood lactate concentration at 75% of V02max were determined 
as that blood pressure and blood lactate concentration recorded during the 
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period in which the V02 was closest to 75% of V02max. The first period in 
which the lactate concentration was greater than 4.5 mmol/1 was determined. 
Ninety percent of the V02max obtained at the preliminary maximal exercise 
test was calculated. The approximate workload at which the V02 was equal to 
90% of the V02max during the preliminary maximal exercise test was recorded. 
For each subsequent maximal test the RPE at this particular workload was 
designated as the RPE at 90% of V02max. For each maximal exercise test the 
workload at which the RPE = 4 was the first workload in which a RPE of four or 
greater was recorded. 
4.3.1.2 Submaximal exercise test 
The submaximal exercise test consisted of prolonged exercise at 75% of the 
subject's initial V02max. After 3 min warm up at 50% of V02max, the workload 
was increased to 75% of V02max and subjects were instructed to pedal for 1 
hour or until a cadence of 70 rpm could no longer be maintained. 
Heart rate, blood pressure, and RPE were recorded every 15 minutes, as 
described above. V02, VC02, Vi and RER were recorded for the last 5 minutes 
in every 15 minute interval by on-line microcomputer as described. The 
duration of exercise was taken as the number of completed minutes performed 
at 75% of V02max. 
Eleven ml of blood were collected from the cannula prior to the 
commencement of exercise and every 15 minutes during exercise for later 
analysis of blood lactate, serum glucose and serum free fatty acid 
concentration. Six ml of the sample were immediately injected into a vacutainer 
(SST Gel and clot activator, L42911) for analysis of serum free fatty acid 
concentration. Four ml were injected into a Vac-U-Test (potassium 
oxalate/sodium fluoride} glass test tube for measurement of serum glucose 
concentration, and the remaining 1 ml was added to a tube containing 2.0 ml of 
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70% perchloric acid for blood lactate analysis. The tubes were inverted to mix 
the contents and were stored on ice until the completion of the test. 
On completion of each submaximal exercise test, the collected blood samples 
were centrifuged at 2000 rpm for 15 min in a Sigma 302-K centrifuge (Munich, 
Germany). After centrifuging, the plasma was removed from the samples for 
glucose and free fatty acid analysis and frozen for subsequent analysis. The 
tubes containing the samples for determination of blood lactate concentration 
were weighed and the supernatant frozen for later analysis as previously 
described. 
Serum free fatty acid concentrations were determined using a standard 
enzymatic kit method (Free Fatty Acids, Half-Micro test, Boehringer Mannheim 
Biochemica, Mannheim, Germany). 
Serum glucose assays were performed on a Technicon RA-XT (Technicon, 
Ireland) automated glucose analyser which operates using the glucose oxidase 
method. The accuracy of the machine was checked by running a standard after 
every 10 samples. 
4.3.2 Short duration, high intensity exercise test 
Short duration, high intensity exercise performance was tested using a 
standardised Wingate test as described by Bar-Or (1987). This test lasts 30 
seconds and requires maximal effort against a supramaximal workload. The 
test was performed on a Monark mechanical cycle ergometer. Before 
beginning the test subjects completed a 2 min warm up. To begin the test, the 
subjects increased the cadence to over 110 revolutions/min against minimal 
resistance. The resistance was suddenly increased to approximately 0.08 
kiloponds per kilogram bodyweight while the subjects pedalled at the highest 
cadence they were able to maintain for 30 seconds. The subjects were 
motivated verbally by the investigator throughout the test. Pedal revolutions 
were counted electronically and recorded by an on-line personal computer. The 
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power output for each 0.5 sec period for the first 5 sec and each 5 sec period 
from 5 to 30 sec was calculated by the computer. Peak power was the highest 
power output for a 0.5 sec period. Mean power over the 30 second test period, 
power to bodyweight ratio, total work done, and average pedal frequency were 
calculated by the computer, using the cadence for each 5 second period, the 
resistance and the subjects bodyweight. The rate of fatigue (W/sec) is the 
difference between the peak power output and the power output over the last 5 
sec divided by the time elapsed between the two measurements. 
4.4 Statistical Analysis 
Data were analysed using analysis of variance (ANOVA) for repeated 
measures, and Duncan's multiple range test to identify the location of 
significant differences. Statistical significance was established at the p<0.05 
confidence level (Ganz 1980). 
With respect to variables measured in the submaximal exercise test, only 
paired data were used: i.e. subjects who were unable to complete 60 min were 
excluded from the analysis from the time that they dropped out. In the analysis 
of RPE during submaximal exercise, all subjects were included throughout the 
test; subjects who did not complete 60 min were given a RPE of 1 O for the time 
points after they had dropped out. 
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Chapter 5. Cardiovascular measurements at rest and side 
effects of ingested medications. 
This chapter will describe the effects of isradipine and atenolol on blood 
pressure and heart rate at rest. The side effects reported during the drug 
treatments will be presented and discussed. 
5.1 Cardiovascular measurements at rest 
Cardiovascular measurements at rest are listed in Table 5.1. Diastolic blood 
pressure at rest, while seated and standing, was significantly decreased by 
both atenolol and isradipine, but was reduced to a greater extent by atenolol 
than isradipine (83.3 mmHg vs 89.0 mmHg vs 96.1 mmHg while seated, (A vs I 
vs P, p=.0001 ). Systolic blood pressure at rest tended to be reduced by both 
agents, but this trend was not statistically significant. Heart rate while seated at 
rest was reduced by atenolol compared to both isradipine and placebo (53 bpm 
Table 5.1 Influence of isradipine, atenolol and placebo on resting cardiovascular parameters. 
Placebo lsradipine 
DBP - Sitting (mmHg) 96.1 ± 2.5 89.0 ± 1.8 
%change .7.4••++ 
SBP - Sitting (mmHg) 145.0 ± 4.7 138.5 ± 3.4 
%change -4.5 
HR - Sitting (bpm) 63.5 ± 2.9 68.1 ± 4.3 
%change 7.2 
DBP - Standing (mmHg) 101.7 ± 2.2 94.1 ±2.0 
%change -7.5**++ 
SBP - Standing (mmHg) 146.9 ± 4.8 140.3 ± 3.5 
%change -4.5 
HR - Standing (mmHg) 68.6 ± 3.3 74.4 ± 4.4 
%change 8.5**++ 
Body Mass (kg) 76.0 ± 4.2 76.2 ± 4.1 
%change 0.3 
Values are expressed as means± SE, n=11. 
**p<.001 isradipine vs placebo, ##p<.001 atenolol vs placebo, ++p<.001 atenolol vs isradipine 















76.4 ± 4.4 
0.5 
vs 68 bpm, 64 bpm, A vs l,P, p=.0001), and was unchanged by isradipine 
compared to placebo. Heart rate while standing was reduced by atenolol 
compared to both isradipine and placebo, but was increased by isradipine 
compared to placebo and atenolol (55.2 bpm vs 74.4 bpm vs 68.6 bpm, A vs I 
vs P, p=.0001). Body weight was unchanged throughout the trial. 
5.2 Discussion 
Whilst ingestion of both atenolol and isradipine lowered blood pressure in this 
group of mildly hypertensive subjects, atenolol reduced the diastolic blood 
pressure by 6 mmHg greater than did isradipine. Thus the two agents did not 
have equipotent blood pressure lowering effects in these subjects at the 
dosages used in this study. 
These subjects demonstrated an increase in heart rate of 6 bpm while standing 
after ingesting isradipine for 4 weeks. The heart rate while seated tended to be 
higher following isradipine ingestion, but this was not statistically significant. 
Most studies investigating the effects of isradipine have reported a mild 
tachycardia (Kirkendall 1988; Nelson et al. 1986; Rupoli et al. 1989), but this is 
not a consistent finding (Chellingsworth et al. 1988; Persson et al. 1989), and 
was found to be transitory in one study (Vermeulen et al. 1988). Tachycardia 
after the ingestion of calcium channel antagonists is thought to be a reflex 
phenomenon due to the vasodilatation and reduced blood pressure (Lund-
Johansen & Omvik 1983). It is possible that these exercise trained subjects are 
more susceptible to postural hypotension resulting from greater venous pooling 
than untrained subjects (Raven & Pawelczyk 1993), and this could explain why 
the tachycardia was present only while standing. 
5.3 Side effects 
Five subjects reported headaches occurring at the beginning of the isradipine 
treatment period. Of these, only 2 subjects required analgesia. No headaches 
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were reported after 5 days with continuing isradipine treatment. Five subjects 
reported that the medication was interfering with their usual exercise training 
whilst ingesting atenolol. Two other subjects reported feeling more tired than 
usual during training whilst ingesting atenolol but did not attribute their 
symptoms to their medication. No other side effects were reported. 
The exercise tolerance of one subject, JF, was so severely compromised 
during the atenolol treatment period (which was his first treatment) that he was 
unable to complete the four weeks on the medication. He described extreme 
fatigue during activities of daily living such as walking to his car. This may have 
been partly due to having run a 56 km marathon a week prior to commencing 
the drug treatment. However, his fatigue rapidly resolved on withdrawal of the 
medication for a 2 week period, and recurred when the medication was 
recommenced. This suggests that atenolol ingestion was responsible for his 
symptoms. He was unable to complete the full duration of atenolol therapy and 
did not undergo exercise testing while on atenolol. He did complete the 
placebo and isradipine treatments and did undergo exercise testing during 
these treatments. Because of the absence of measures of exercise 
performance during the atenolol treatment this subject's results have been 
excluded from the analysis. However, the severe impairment of physical activity 
apparently caused by atenolol in this subject should be noted. 
It has been reported in the literature that the fatiguing effects of B-blockers are 
more marked in some individuals than in others (Kaiser et al. 1981). It appears 
that this subject, JF, is particularly sensitive to this effect of atenolol. Hence the 
study population in this thesis should be described as only those physically 
active hypertensive patients who are able to tolerate both atenolol and 
isradipine treatments and who are able to participate in regular physical activity 
while ingesting these medications. 
It is noteworthy that whereas 7 subjects reported increased fatigue during 
exercise whilst ingesting atenolol, no subject described increased fatigue 
during exercise whilst ingesting isradipine or placebo. It is possible that there 
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was some bias in the reporting of side effects, as most of these subjects were 
runners who were well informed on the effects of ~-blockade and who were 
accustomed to measuring their resting pulse rate. Nevertheless, fatigue during 
physical exercise was an important side effect of the atenolol treatment, as this 
particular side effect may lead to poor compliance in hypertensive subjects who 
are physically active. This is consistent with the literature; ~-blockers are well 
known to cause subjective feelings of increased fatigue during physical activity 
(Van Bortel & Van Baak 1992). Complaints of impaired exercise capacity are 
rare in patients ingesting calcium channel blockers (Lund-Johansen 1987). 
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Chapter 6. Comparative effects of isradipine and atenolol on 
maximal exercise performance in physically active 
hypertensive patients. 
6.1 Introduction 
The results of studies on the effects of calcium channel antagonists on 
maximal exercise performance are conflicting. Verapamil and diltiazem 
ingestion have been shown to be without effect on maximal exercise capacity 
in normotensive or hypertensive subjects (Derman et al. 1991 b; Keleman et al. 
1989; Myburgh and Gordon 1987; Szlachcic et al. 1987; Vanhees et al. 1988). 
Similarly, nifedipine ingestion is also without effect on V02max, WLmax or 
maximal exercise test duration when administered to hypertensive patients 
(Ashmore et al. 1990; Gosse et al. 1992; Halperin et al. 1993). Similarly, 
neither V02max nor WLmax was altered following lacidipine or amlodipine 
administration (Fariello et al. 1991; Gillies et al. 1996). However, it appears that 
nifedipine ingestion results in a small impairment of maximal exercise capacity 
in normotensive subjects (Chick et al. 1986; Derman et al. 1992; Gordon et al. 
1986, 1987). 
The cause of the impairment of maximal exercise performance after nifedipine 
ingestion in normotensive subjects is not clear. As discussed in Chapter 2, it is 
possible that the reason for this discrepancy is related to the physical activity 
status of the subjects. Investigations into the effects of dihydropyridine 
treatment on exercise performance in hypertensive subjects who are physically 
active and consequently have a high capacity to perform maximal exercise are 
required. 
Studies which have examined the effects of ~-blockers on maximal exercise 
performance in physically active hypertensive subjects have reported a 
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reduction in maximal exercise capability following ~-blockade (Szlachcic et al. 
1987; Van Baak et al. 1988). 
Thus, it is important to investigate the effects of anti-hypertensive agents on 
maximal exercise performance in hypertensive individuals who are physically 
active. The effects of isradipine on maximal exercise performance are 
unknown. This chapter compares the effects of isradipine and atenolol on 
incremental exercise to exhaustion in physically active hypertensive subjects. 
6.2 Methods 
The effects of isradipine and atenolol on maximal exercise performance in 
active subjects with mild to moderate essential hypertension were compared in 
a placebo controlled, crossover study where drug treatments were randomised 
and double blinded. The study design is described in Chapter 4. 
6.3 Results 
The influence of isradipine and atenolol on cardiovascular and respiratory 
parameters and exercise performance during incremental exercise to 
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Placebo Atenolol lsradipine 
Figure 6.1 Maximum oxygen consumption following ingestion of anti-hypertensive medication. 
*p<.05 atenolol vs placebo, isradipine. Values +/- SE. 
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Table 6.1. Influence of isradipine, atenolol and placebo on physiological measurements during 
incremental exercise to exhaustion in physically active hypertensive patients. 
Placebo 
Maximum HR 170.7 ± 2.2 
(bpm) 
V02max (ml02/kg/min) 36.4 ± 1.8 
% change 
Peak workload (W) 243 ± 19 
%change 
Test duration (min) 9.5±1.1 
%change 
Peak minute ventilation 91.7 ± 6.5 
%change (I/min) 
REA at maximum exercise 1.13 ± 0.015 
Systolic BP at 75%V02max 195.0 ± 9.1 
(mmHg) 
Diastolic BP at 75%V02max 94.0 ± 2.7 
(mmHg) 
APE at 90% of V02max 5.7 ± 0.7 
Workload at APE = 4 195 ± 11 
(W) 
Values are expressed as means ± SE 
* p<.05 atenolol vs placebo, ## p<.005 atenolol vs placebo, 
+p<.05 atenolol vs isradipine, ++p<.005 atenolol vs isradipine 
lsradipine Atenolol 
171.6 ± 1.9 130.2 ± 6.3##++ 
36.1 ± 1.9 33.6 ± 1.5#+ 
-0.8 -7.7 
229 ± 18 214±15## 
-5.8 -11.9 
8.6 ± 1.1 7.8 ± 0.9# 
-9.5 -17.9 
90.8 ± 7.3 82.1 ± 6.4#+ 
-1.0 -10.5 
1.13 ± 0.018 1.13±0.021 
197.0 ± 6.3 110.5 ± 8.7**++ 
91.0 ± 3.1 88.0 ± 2.9 
6.9 ± 0.6 7.0 ± 0.7 
179 ± 12 181 ± 11 
Abbreviations: V02max=maximum oxygen consumption, HR=heart rate, RER=respiratory exchange ratio, 
BP=blood pressure, RPE=rating of perceived exertion. 
Maximum heart rate was decreased following ingestion of atenolol only (130 vs 
171 vs 172 bpm, A vs P vs I, p<0.001). 
V02max was reduced after atenolol but unchanged after isradipine ingestion 
(33.6 vs 36.4, 33.6 vs 36.1 ml02/kg/min, A vs P, A vs I, p<.05} (Figure 6.1 ). 
Peak workload (214 vs 243 W, A vs P, p<.01) (Figure 6.2), test duration (7.8 vs 
9.5 min, A vs P, p<.05), and peak Vi (82.1 vs 91.7 I/min, A vs P, p<.05) were 
similarly reduced following atenolol ingestion compared to placebo. There was 
no significant difference in these parameters following isradipine ingestion, 
when compared either to placebo or atenolol treatments. 
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Figure 6.2 Peak workload achieved in incremental exercise to exhaustion following ingestion of 
anti-hypertensive medication. 
*p<.01 atenolol vs placebo. Values +/- SE. 
Systolic blood pressure while cycling at 75% of V02max was decreased 
following atenolol only (171 vs 195 vs 197 mmHg, A vs P vs I, p<.001). 
RPE at 90% of V02max and the workload at which a RPE of 4 was reported, 
were unaltered following ingestion of either isradipine or atenolol. 
Blood lactate concentrations were similarly unaffected following ingestion of 
either isradipine or atenolol (Table 6.2). Neither the maximum blood lactate 
concentration, the lactate concentration at 75% of V02max nor the time at 
Table 6.2. Influence of isradipine, atenolol and placebo on blood lactate concentrations during 
incremental exercise to exhaustion in physically active hypertensive patients. 
Placebo lsradipine Atenolol 
Peak lactate cone. 9.11 ± 0.71 8.42 ± 1.02 8.28 ± 0.97 
(mmol/1) 
Time when blood lactate 6.7 ± 1.5 6.3 ± 1.4 7.1 ± 1.3 
cone. > 4.5 mmol/1 (min) 
Blood lactate cone. at 3.17 ± 0.49 3.65 ± 0.55 2.87 ± 0.50 
75%V02max (mmol/1) 
Values are expressed as means ± SE 
Abbreviations: conc=concentration, 75%V02max=75% of maximum oxygen consumption. 
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which the blood lactate concentration exceeded 4.5 mmol/1 were altered by 
either agent. 
6.4 Discussion 
The principal finding of this study was that in hypertensive subjects who are 
able to maintain regular physical activity while ingesting isradipine and atenolol, 
maximal exercise performance, measured as V02max, peak workload and test 
duration, was reduced after atenolol ingestion compared to placebo, but 
unaltered following ingestion of isradipine compared to placebo. 
V02max was reduced by almost 8% after atenolol, which is consistent the 
extent of exercise intolerance described in previous reports (Van Baak 1988). 
That no reduction in maximal exercise capacity was seen following ingestion of 
isradipine concurs with the finding of authors who studied sedentary 
hypertensive subjects ingesting the dihydropyridine derivatives, nifedipine, 
amlodipine and lacidipine (Ashmore et al. 1990; Fariello et al. 1991; Gosse et 
al. 1992; Halperin et al. 1993). It also concurs with the study by Gillies et al. 
(1996) who found that maximal exercise performance was unaltered following 
amlodipine ingestion in hypertensive patients who were physically active. 
The mean V02max of the hypertensive subjects in this study was 38 
mlOikg/min. This is higher than the mean V02max of the subjects in the 
studies on sedentary hypertensive subjects and also higher than the mean 
V02max of subjects in the study on physically active hypertensive patients by 
Gillies et al. (1996). However it is not as high as the mean V02max of subjects 
in the studies on normotensive subjects which found an impairment of maximal 
exercise capacity following nifedipine ingestion in normotensive subjects 
(Chapter 2). Hence, it is still unclear whether it is the physical activity status of 
subjects, the presence of hypertension, or differences between nifedipine and 
the other dihydropyridine derivatives, which determines if dihydropyridine 
ingestion results in impaired maximal exercise performance. 
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V02max was reduced following atenolol ingestion compared to both placebo 
and isradipine. However, whilst peak workload and test duration following 
atenolol ingestion were decreased compared to placebo, there was no 
difference in peak workload and test duration following atenolol ingestion 
compared to these parameters following isradipine ingestion. Thus, there was 
a trend for peak workload and test duration to be reduced following isradipine 
ingestion. 
Maximum heart rate was reduced following ingestion of atenolol but not 
isradipine. This finding is consistent with numerous studies where ~-blockade 
has been found to reduce exercise heart rate (Frisk-Holmberg et al. 1985; 
Gordon & Duncan 1991; Joyner et al. 1986; Scruggs et al. 1991; Szlachcic et 
al. 1987; Tesch 1985; Van Baak 1988). The finding that isradipine ingestion did 
not alter maximum heart rate also concurs with reports that maximum heart 
rate is unaltered after dihydropyridine derivative administration (Cantor & 
Cristal 1990; Fariello et al. 1991; Gillies et al. 1996; Halperin et al. 1993). 
Systolic blood pressure during the graded exercise test was reduced following 
ingestion of atenolol but not isradipine. This finding concurs with the results of 
many studies which have established that ~-blockade reduces systolic blood 
pressure during exercise (Franz & Wiewel 1984; Joyner et al. 1986; Lund-
Johansen 1987; Myburgh & Gordon 1987; Van Baak 1988; Yamakado et al. 
1983). Most studies report that, in hypertensive subjects, both systolic and 
diastolic blood pressure are reduced by dihydropyridine derivatives at maximal 
and submaximal levels of exercise (Ashmore et al. 1990; Cantor & Cristal 
1990; Fariello et al. 1989; Franz & Wiewel 1984; Lund-Johansen et al. 1992; 
Omvik et al. 1988). However, other authors have reported that systolic blood 
pressure during submaximal exercise is unaltered after nifedipine, amlodipine 
and isradipine administration (Gillies et al. 1996; Halperin et al. 1993; Klein et 
al. 1983; Mayer et al. 1991 ), as was the finding in this study. The reasons for 
this discrepancy are not directly apparent, but may be due to differences in the 
exercise protocol used, with those studies finding a reduction in systolic blood 
pressure during exercise after dihydropyridine treatment tending to use an 
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exercise protocol of lower exercise intensity than those which did not show a 
reduction in systolic blood pressure during exercise. 
RPE were unaltered by either agent in this study. It is difficult to explain why 
the RPE were unchanged after atenolol ingestion as there was a reduction in 
maximal exercise capacity with atenolol. Whilst there was a trend for the RPE 
to be higher after ingestion of atenolol, this did not achieve statistical 
significance. It is possible, however, that had the study sample been larger, this 
trend may have reached statistical significance. 
Blood lactate concentrations were unchanged during and after the maximal 
exercise test following either isradipine or atenolol ingestion compared to 
placebo. This finding concurs with findings in other studies on dihydropyridine 
derivatives (Derman et al. 1992; Gillies et al. 1996; Kindermann 1987) although 
some authors have reported an increase in blood lactate concentration during 
exercise following dihydropyridine ingestion in normotensive subjects (Chick et 
al. 1986; Raffestin et al. 1985). Blood lactate concentrations during 
submaximal and high intensity exercise after ~-blockade are reported as being 
unchanged (Derman et al. 1992; Lundborg et al. 1981; Van Baak et al. 1987b), 
increased (Broberg et al. 1988) and decreased (Verstappen & Van Baak 
1987). 
Thus, the results of this study demonstrate that maximal exercise performance 
is unaltered after isradipine ingestion in physically active hypertensive patients 
who are able to maintain regular physical activity while ingesting isradipine and 
atenolol. However, atenolol ingestion by these subjects results in impaired 
maximal exercise capacity. 
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Chapter 7. Comparative effects of isradipine and atenolol on 
prolonged submaximal exercise performance in physically 
active hypertensive patients. 
7.1 Introduction 
Whilst graded exercise to exhaustion is frequently used to assess exercise 
capacity, it is clearly not the type of exercise which humans typically perform. 
Most recreational and occupational forms of exercise require effort at a 
submaximal intensity over a far longer duration than that involved in a maximal 
exercise test. As the physiological mechanisms determining maximal and 
submaximal exercise capacity differ, it is important to conduct prolonged 
submaximal exercise testing when investigating the effects of pharmacological 
agents or other interventions on exercise performance. 
Mclenachan et al. (1991) reported that there was no difference between the 
effect of two ~-blockers, celiprolol and atenolol, on maximal exercise capacity. 
However, atenolol, but not celiprolol, increased subjective indices of 
breathlessness and fatigue during submaximal exercise. This finding indicates 
that submaximal exercise testing may demonstrate differences between anti-
hypertensive agents that are not detected with maximal exercise testing. 
Studies which have examined the effects of ~-blockade on prolonged 
submaximal exercise performance report that the time to exhaustion during this 
form of exercise is reduced by 10-50% following the ingestion of ~-blocking 
agents (Van Baak 1988; Van Bertel et al. 1991; Vanhees et al. 1988). 
However, most studies report that these agents reduce maximal exercise 
performance by only 4-10%. This finding further suggests that the effects of 
anti-hypertensive medications may become most apparent during prolonged 
submaximal exercise testing. 
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Submaximal exercise capacity in normotensive or hypertensive subjects is 
unchanged following ingestion of verapamil or diltiazem (Derman et al. 1991 b, 
Herbertsson & Fagher 1990; Mooy et al. 1987; Vanhees et al. 1988). Similarly, 
Gillies et al. (1996) found that prolonged submaximal exercise performance 
was unaltered after ingestion of the dihydropyridine derivative, amlodipine, by 
physically active hypertensive patients. Further research is required to 
determine the effects of other dihydropyridine calcium channel blockers on 
prolonged submaximal exercise performance. 
The capacity of the active skeletal muscle to oxidise lipids during prolonged 
submaximal exercise is decisive in order to spare consumption of glucose and 
glycogen stores and hence prolong activity. It is possible that this capacity is 
altered after drug ingestion. Therefore, it is important to demonstrate any 
alteration of substrate fuel kinetics during exercise and so to measure indices 
of fuel substrate utilisation when examining the effects of agents on prolonged 
submaximal exercise. 
Accordingly, this chapter investigates the effects of isradipine and atenolol on 
prolonged submaximal exercise performance and on cardiovascular, 
respiratory and metabolic parameters during submaximal exercise in physically 
active hypertensive patients. 
7.2 Methods 
The effects of isradipine and atenolol on prolonged submaximal exercise 
performance in physically active subjects with mild to moderate essential 
hypertension were compared in a placebo controlled, crossover study where 
drug treatments were randomised and double blinded. The study design is 
described in Chapter 4. 
Briefly, after a 3 min warm up, subjects pedalled at a workload of 75% of their 
initial V02max for one hour, or until a cadence of 70 rpm could no longer be 
maintained. 
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Figure 7.1 Number of tests in which time to exhaustion was greater than each 15 minute interval. 
7.3 Results 
Figure 7.1 shows the number of tests completed at the end of each 15 min 
interval. Whilst 8 subjects were able to cycle for over 45 minute~ following 
ingestion of placebo, only 3 subjects completed 45 minutes after ingestion of 
isradipine and 2 subjects completed 45 minutes after ingestion of atenolol. 
The mean time to exhaustion for each treatment is depicted in Figure 7.2. Both 
atenolol and isradipine ingestion reduced the time to reach exhaustion at 
75%V02max (27.8, 34.4 vs 46.4 min, A,I vs P, p<.005). The time to exhaustion 
after isradipine ingestion was not significantly different to that after atenolol 
ingestion. 
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Figure 7.3 Systolic BP during exercise at 75%V02max. 





Systolic blood pressure during submaximal exercise is shown in Figure 7.3 .. 
Systolic blood pressure after placebo ingestion at 30 min of exercise at 75% of 
V02max was 211 mmHg. Systolic blood pressure while cycling at 75% of 
V02max was reduced by atenolol at both 15 min and 30 min (p<.001 A vs P,I). 
Systolic blood pressure during submaximal exercise was not altered after 
isradipine ingestion. 
Changes in heart rate during the submaximal test are shown in Figure 7.4. 
















Figure 7.4 Heart rate during exercise at 75%V02max. 

























•p<.05 atenolol vs placebo at 15 min, #p<.05 atenolol vs placebo, isradipine at 30 min. Values +/-SE. 
A vs P,I). Heart rate during submaximal exercise after isradipine ingestion was 
not different to that after taking placebo. 
RPE during submaximal exercise are shown in Figure 7.5. RPE following 
ingestion of placebo increased during submaximal exercise from 2.6 at 15 min 
to 8.3 at 45 min. RPE was increased during exercise after atenolol ingestion 
compared to placebo at 15 min and by both atenolol and isradipine compared 
to placebo at 30 min. By 45 min, too many subjects had terminated their tests 
(and so received a RPE of 10), for the differences in RPE between treatments 
and placebo to be significant. 
Maximum oxygen consumption, RER and Vi measured at 15 min and at 30 min 
of submaximal exercise are shown in Table 7.1. RER decreased during 
exercise after ingestion of placebo, of isradipine and of atenolol. V02, RER and 
Vi were not significantly different following ingestion of the different agents. 
Similarly, blood lactate, glucose and free fatty acid concentrations were not 
altered after the ingestion of either isradipine or atenolol. (Table 7.2). 
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Table 7.1. Influence of isradipine, atenolol and placebo on oxygen consumption, 
respiratory exchange ratio and minute ventilation during prolonged submaximal 
exercise in physically active hypertensive patients. 
15 min 30min 
n=7 n=5 
V02 (ml02/kg/min) 
Placebo 28.9 ± 1.6 29.9 ± 4.4 
lsradipine 29.7 ± 1.5 30.2 ± 3.8 
Atenolol 29.3 ± 1.5 28.9 ± 4.3 
RER 
Placebo 1.00 ± 0.02 0.98 ± 0.01 
lsradipine 0.99 ± 0.01 0.95 ± 0.01 
Atenolol 1.01 ± 0.01 0.98 ± 0.02 
V; (I/min) 
Placebo 68.8 ± 6.4 73.0 ± 6.0 
lsradipine 69.6 ± 5.4 73.6 ± 3.8 
Atenolol 67.5 ±4.3 69.3 ± 6.3 
Values are expressed as means ± SE. 
Abbreviations: V02=oxygen consumption, RER=respiratory exchange ratio, V;=minute ventilation. 
7.4 Discussion 
The first important finding of this study was that submaximal endurance time 
was substantially reduced by both atenolol and isradipine. Subjects were able 
to cycle at 75% V02max for 46 min after placebo ingestion compared to 28 and 
34 minutes following ingestion of atenolol and isradipine respectively. This 
Table 7.2. Influence of isradipine, atenolol and placebo on blood lactate, glucose and 
free fatty acid concentrations during prolonged submaximal exercise in physically 
active hypertensive patients. 
Rest 15 min 30min 
n=9 n=9 n=4 
Lactate (mmol/1) 
Placebo 2.12 ± 1.06 5.95 ± 0.75 5.34 ± 1.44 
lsradipine 1.68 ± 0.50 6.28 ± 0.56 7.69 ± 2.42 
Atenolol 1.06 ± 0.08 6.59 ± 0.66 6.45 ± 1.39 
Glucose (mmol/1) 
Placebo 6.84 ± 0.40 6.26 ± 0.31 7.27 ± 0.97 
lsradipine 7.88 ± 0.51 5.79±0.19 5.90 ± 0.40 
Atenolol 6.39 ± 0.25 5.84 ± 0.50 6.60 ± 0.40 
Free fatty acid (mmol/1) 
Placebo 0.31 ± 0.06 0.20 ± 0.03 0.18 ± 0.05 
lsradipine 0.27 ± 0.05 0.15 ± 0.01 0.24 ± 0.03 
Atenolol 0.24 ± 0.04 0.15 ± 0.04 0.17 ± 0.04 
Values are expressed as means ± SE. 
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represents a reduction in endurance time of 39% and 26% respectively. The 
difference between the endurance times for atenolol and isradipine were, 
however, not significant. 
The reduction in submaximal exercise performance following ingestion of 
atenolol corresponds to that reported in the literature (Lundborg et al. 1981; 
Van Baak 1988). Only one study has reported on the effect of dihydropyridine 
calcium channel blockers on prolonged submaximal exercise where the 
subjects have exercised to exhaustion. Gillies et al. (1996) found that 
amlodipine administration to physically active hypertensive patients had no 
effect on prolonged submaximal exercise endurance. The study by Gillies et al. 
(1996) is similar to this study in that the subjects in both studies had similar 
initial values of blood pressure (147/103 mmHg vs 155/100 mmHg 
respectively), V02max (34 mlOikg/min vs 38 ml02/kg/min) and prolonged 
submaximal exercise time to exhaustion after placebo ingestion (44 min. vs 46 
min). The similarity between this study and the study by Gillies et al. (1996) 
suggests that the difference between the effect of isradipine ingestion and 
amlodipine ingestion on submaximal exercise performance is due to a 
difference between the two agents. In fact, the effect of amlodipine ingestion 
on resting blood pressure was different to that of isradipine, in that amlodipine 
did not significantly alter resting blood pressure compared to placebo (Gillies et 
al. 1996), whereas isradipine reduced diastolic blood pressure at rest 
compared to placebo. This is further evidence that amlodipine and isradipine at 
doses used in the 2 studies have different effects on the physiology of the 
subjects. 
The second important finding of this study was that APE was increased by both 
agents compared to placebo at 30 min and by atenolol compared to placebo at 
15 min. 
As blood lactate, glucose and free fatty acid concentrations and V02, REA, Vi 
during submaximal exercise were not different between treatment periods, the 
increase in APE and reduction in time to exhaustion seen after isradipine and 
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atenolol ingestion cannot be attributed to changes in these parameters. 
Further, as heart rate and blood pressure during submaximal exercise were 
unaltered after isradipine ingestion, the increase in RPE and reduction in time 
to exhaustion during submaximal exercise after isradipine ingestion cannot be 
attributed to changes in heart rate and blood pressure during exercise. 
Submaximal oxygen consumption, Vi, and RER were not altered by either 
atenolol or isradipine. Some authors have reported small reductions in V02 and 
Vi after ~-blockade (Frisk-Holmberg et al. 1985; Pearson et al. 1987) but others 
have reported that these indices are unchanged (Dodd et al. 1988; Van Baak 
1988). V02, Vi, and RER for a given submaximal workload have been reported 
to be unchanged after dihydropyridine derivatives in normotensive and 
hypertensive subjects (Derman et al. 1992; Gillies et al. 1996; Kindermann 
1987; Omvik et al. 1988). Hence, there appears to be little effect of atenolol or 
isradipine on gas exchange during exercise. 
As serum concentrations of glucose, lactate and free fatty acids and RER 
during submaximal exercise were not altered following ingestion of either 
atenolol or isradipine compared to placebo, it is unlikely that alterations in the 
kinetics of energy production for active muscle cause the impaired exercise 
endurance demonstrated with both these agents. Other investigators have 
reported that serum glucose and blood lactate concentrations during 
submaximal exercise are unchanged after ~-blockade (Lundborg et al. 1981; 
Van Baak et al. 1993), which concurs with the findings in this study. 
While most investigators report that serum free fatty acid concentrations during 
exercise are reduced after ~-blockade (Van Baak 1988), this is not a consistent 
finding (Wijnen et al. 1993). Derman (1993) found that free fatty acid 
concentrations were reduced during prolonged submaximal exercise only after 
40 min of exercise. Similarly, Lundborg et al. (1981) report that the 
concentration of free fatty acids was significantly reduced after propranolol only 
after exercising for an hour and only after a longer period than this for the ~1-
selective blocker, metoprolol. In this study, subjects were exercising at a 
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relatively higher workload and became exhausted earlier, so that data were 
only available up to 30 min of exercise. A reduction in free fatty acid 
concentration was not seen in this study. This demonstrates that the reduction 
in exercise endurance caused by atenolol is not related to free fatty acid 
availability. As outlined in Chapter 3, other studies have shown that it is unlikely 
that the reduction in exercise tolerance with P-blockers is related to the 
availability of free fatty acids (Van Baak et al. 1993). 
In concordance with this study, serum lactate and glucose concentrations 
during submaximal exercise after calcium channel antagonist administration 
have previously been reported as being unchanged (Van Baak et al. 1987b, 
Derman et al. 1992; Gillies et al. 1996; Halperin et al. 1993; Kindermann 1987). 
Heart rate and blood pressure during exercise were unaltered by isradipine. 
Exercising heart rate in hypertensive subjects has previously reported to be 
unchanged by dihydropyridine derivatives (Fariello et al. 1989; Halperin et al. 
1993; Lund-Johansen et al. 1992; Omvik et al. 1988). Most reports show that 
these agents decrease systolic and diastolic blood pressure during submaximal 
exercise (Fariello et al. 1989; Gillies et al. 1996; Lund-Johansen et al. 1992; 
Omvik et al. 1988). However, other studies have demonstrated that systolic 
blood pressure is maintained in hypertensive subjects during submaximal 
exercise despite normalisation of the resting blood pressure (Halperin et al. 
1993; Klein et al. 1983; Mayer et al. 1991 ). The findings of our study are in 
accordance with these latter studies. 
Heart rate and systolic blood pressure during submaximal exercise were 
reduced by atenolol compared to placebo, which is in agreement with previous 
findings (Lundborg et al. 1981; Van Baak 1988). 
The finding that both isradipine and atenolol impaired prolonged submaximal 
exercise capacity, whilst atenolol, but not isradipine, reduced maximal exercise 
capacity (Chapter 6), verifies the conclusion of McLenachan et al. (1991 ), that 
it is important to perform submaximal exercise testing in order to demonstrate 
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differences between anti-hypertensive agents. These differences are 
important, as submaximal exercise is the type of exercise which is most 
commonly performed by hypertensive patients. 
In conclusion, the major findings of this study are that, in hypertensive patients 
who are able to maintain regular physical activity whilst ingesting atenolol and 
isradipine, submaximal endurance time was substantially reduced. 
Furthermore, RPE at 30 min were increased by both atenolol and isradipine 
compared to placebo. This reduction in prolonged submaximal exercise 
performance cannot be attributed to changes in serum lactate, glucose or free 
fatty acid concentrations or V02, RER, Vi during submaximal exercise. 
Moreover, the reduction in time to exhaustion during submaximal exercise 
following isradipine ingestion is not a result of changes in heart rate or blood 
pressure during submaximal exercise. The cause of the reduction in 
submaximal exercise performance following atenolol or isradipine ingestion is 
not directly apparent. 
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Chapter 8. Comparative effects of isradipine and atenolol on 
short duration high intensity exercise performance in 
physically active hypertensive patients. 
8.1 Introduction 
It was shown in Chapter 7 that submaximal exercise endurance was reduced 
after isradipine ingestion without alterations in blood pressure, heart rate, V02, 
REA, Vi or blood lactate, glucose or free fatty acid concentrations during 
exercise. This finding suggests that the premature fatigue results from 
mechanisms other than those affecting central haemodynamics, ventilation or 
substrate delivery during exercise. 
It is possible that the site of the premature fatigue during exercise induced by 
~-blockade and also by other anti-hypertensive agents is due to alteration of 
skeletal muscle contraction and recruitment (Derman et al. 1991 a). 
Furthermore, Noakes (1988) has suggested that it is failure of muscle 
contractility which determines the onset of fatigue, rather than limitations of 
oxygen delivery ~nd utilisation. 
The Wingate Anaerobic Test is a 30 sec bout of supramaximal exercise where 
the there is a high flux through oxygen independent pathways. This test has 
been shown to be highly reliable and reproducible (Bar-Or 1987). Hence, the 
Wingate Anaerobic Test is suitable to investigate the effects of anti-
hypertensive agents on short duration high intensity exercise. As performance 
in a Wingate test is likely to be diminished when skeletal muscle contractile 
function is impaired, the Wingate test also provides a measure of skeletal 
muscle contractile function. 
Few studies have examined the effects of calcium channel antagonists on 
skeletal muscle contractile function. Accordingly, this chapter examines the 
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effects of isradipine and atenolol on short duration high intensity exercise in 
active subjects with mild to moderate essential hypertension. 
8.2 Methods 
The study design is described in Chapter 4. Briefly, short duration, high 
intensity exercise performance was tested using a standard Wingate test as 
described by Bar-Or (1987). 
8.3 Results 
Technical problems with the equipment prevented data collection for 3 
subjects. Results of the Wingate test were obtained for the remaining 8 
subjects and are listed in Table 8.1. Neither isradipine nor atenolol influenced 
peak skeletal muscle power attained. The mean skeletal muscle power output 
over the 30 second test was also unaffected by either agent. Hence, the 
variables, power to weight ratio and total work done, which are dependent on 
the power output indices, were similarly unaffected following ingestion of 
isradipine or atenolol compared with placebo. The rate of fatigue during the 
test and the average pedal frequency were also unaltered following ingestion of 
either agent compared to placebo. 
Table 8.1. Influence of isradipine, atenolol and placebo on short duration, high intensity exercise 
performance in active hypertensive patients. 
Wingate test parameters Placebo lsradipine Atenolol 
Peak power (W) 603 ± 59 568 ± 83 581 ± 55 
Mean power (W) 477 ± 56 420 ± 63 445 ± 55 
Power:weight ratio (W/kg) 7.83 ± 0.51 7.38 ± 0.76 7.72 ± 0.48 
Total work done (J) 28734 ± 3394 25189 ± 3752 26683 ± 3277 
Average pedal frequency 87.5 ± 7.4 77.5 ± 9.8 81.4±7.5 
(revs/min) 
Fatigue rate (W/sec) 8.0±1.1 8.4 ± 1.2 9.3 ± 0.9 
Values are expressed as means ± SE. n = 8. 
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8.4 Discussion 
This study found that, in hypertensive subjects who are able to maintain regular 
physical activity while ingesting isradipine and atenolol neither of these agents 
impaired the ability to perform short duration, high intensity exercise. Thus, 
power output during high intensity exercise of short duration measured during 
the Wingate test was not affected following ingestion of either atenolol or 
isradipine compared with placebo. The premature fatigue during prolonged 
submaximal exercise found after isradipine and atenolol ingestion is therefore 
not due to the inability of skeletal muscle to perform short duration, high 
intensity exercise. 
This finding concurs with those of Gillies et al. (1996) and of Derman et al. 
(1993) where a tests of skeletal muscle contractile properties were unaffected 
following calcium channel antagonism. Derman et al. (1993) examined the 
effects of diltiazem in normotensive subjects on power output during bouts of 
maximum effort on an isokinetic cycle ergometer. Diltiazem had no effect on 
peak power, average power and work done at a variety of crank velocities 
during 10 second tests, or on total work done and rate of work decline during a 
30 second isokinetic exercise test. Gillies et al.(1996) investigated the effects 
of amlodipine ingestion on skeletal muscle function by measuring the time 
taken for the torque produced by maximum voluntary isometric contractions of 
the quadriceps muscle to fatigue to 70% of the strength of the initial 
contraction. These authors found that amlodipine ingestion by physically active 
hypertensive patients did not alter skeletal muscle function either before of 
after prolonged submaximal exercise. 
This finding also concurs with most studies which have examined the effect of 
P-blockers on skeletal muscle power output during high intensity exercise of 
short duration, which report no effect of P-blockade on the ability to generate 
power (Derman et al. 1993; Rusko et al. 1980; Yoroko et al. 1990). However, 
others have found a reduction in power output during high intensity exercise of 
short duration following P-blockade (Kaiser 1984 ). 
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While most tests of skeletal muscle contractile properties have been found to 
be unaffected by P-blockade (Alway et al. 1988; Derman et al. 1993; Rusko et 
al. 1980), subjects who fatigue prematurely after P-blockade have reduced 
muscle power output during short term, high intensity exercise when it is 
measured immediately after the completion of prolonged submaximal exercise 
(Derman et al. 1991 a; Karlsson et al. 1983). This finding provides evidence that 
there is impaired skeletal muscle contractile function after exercise following P-
blockade. Further, in the study by Derman et al. (1991 a), subjects who 
terminated exercise prematurely following P-blockade had increased integrated 
electromyographic activity and increased minute volume during prolonged 
submaximal exercise. This suggests that the subjects had an alteration in 
skeletal muscle recruitment patterns and increased perception of effort after P-
blockade, perhaps as a result of impaired skeletal muscle function. It is 
possible that skeletal muscle function may also be impaired during or after 
prolonged submaximal exercise after ingestion of calcium channel antagonists. 
Gillies et al. (1996) did not find evidence of impaired skeletal muscle function, 
measured by the torque achieved during maximal voluntary isometric 
contractions of the quadriceps muscle, after prolonged submaximal exercise 
following amlodipine ingestion. However, this study did not demonstrate an 
impairment of submaximal exercise performance after amlodipine ingestion. It 
is important that further research is done to investigate the effects of isradipine, 
or other calcium channel blockers which are found to impair submaximal 
exercise performance, on skeletal muscle function after prolonged submaximal 
exercise. 
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Chapter 9. Summary and conclusions. 
The principal finding of this thesis is that, in hypertensive patients who are able 
to maintain regular physical activity whilst ingesting atenolol and isradipine, 
prolonged submaximal exercise performance was impaired after ingestion of 
isradipine and of atenolol compared to placebo, whilst maximal exercise 
performance is reduced after ingestion of atenolol only. 
Submaximal exercise endurance was impaired equally after atenolol and 
isradipine. The reduction in submaximal exercise endurance of 40% seen after 
atenolol ingestion is consistent with reports in the literature, where the time to 
exhaustion during prolonged submaximal exercise is reported to be reduced by 
10-50% by the ingestion of ~-blocking agents (Van Baak 1988; Van Bortel et al. 
1991; Vanhees et al. 1988). 
Maximal exercise capacity was reduced after atenolol ingestion with an 8% 
reduction in V02max. Peak workload, test duration and Vi were 
correspondingly reduced during ~-blockade with atenolol. No impairment of 
maximal exercise was seen with isradipine. 
APE during submaximal exercise was raised after atenolol and isradipine 
ingestion. Neither agent altered submaximal exercise Vi or V02 suggesting that 
the impairment in exercise endurance is not due to changes in ventilation or 
the provision and utilisation of oxygen by the muscles. Neither agent altered 
REA, blood lactate, glucose or free fatty acid concentrations during prolonged 
submaximal exercise. This finding suggests that the reduction in submaximal 
exercise performance was not due to an impairment of energy production for 
active muscle following either atenolol or isradipine ingestion. 
Submaximal exercise blood pressure and heart rate were reduced by atenolol 
but were unaffected by isradipine. Hence, premature fatigue and increased 
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APE during prolonged submaximal exercise after isradipine ingestion cannot 
result from changes in blood pressure or heart rate during exercise. 
The conclusion that both atenolol and isradipine reduced submaximal exercise 
capacity, while atenolol, but not isradipine, decreased maximal exercise 
performance, demonstrates the importance of performing tests of submaximal 
exercise endurance in order to reveal an effect on exercise capacity of an anti-
hypertensive medication. lsradipine ingestion did not reduce maximal or short 
duration, high intensity exercise capacity but did cause a reduction in 
prolonged submaximal exercise capacity which was equal to that of atenolol. 
This is significant as submaximal exercise is the form of exercise testing most 
analogous to the exercise that most individuals actually perform. 
The second important finding in this study is that neither isradipine nor atenolol 
affected the ability to perform short duration, high intensity exercise. Power 
output during short duration, high intensity exercise as measured in the 
Wingate test was not affected by either atenolol or isradipine. The premature 
fatigue during prolonged submaximal exercise found after isradipine and 
atenolol ingestion is therefore not due to factors which would also limit the 
ability of skeletal muscle to perform short duration, high intensity exercise 
before a bout of prolonged exercise. As outlined in Chapter 8, there is 
evidence that after ~-blockade, skeletal muscle contractile function is impaired 
immediately following prolonged submaximal exercise in those subjects who 
become fatigued prematurely during the prolonged exercise bout (Derman et 
al. 1991 a; Karlsson et al. 1983). It is possible that calcium channel antagonists 
which reduce submaximal exercise performance might also impair skeletal 
muscle function during prolonged submaximal exercise. Further research is 
required to investigate if this effect does indeed occur. 
The dosages of isradipine and atenolol used in this study were not equipotent. 
Atenolol reduced resting blood pressure by approximately 5 mmHg more than 
did isradipine. lsradipine has a dose dependent effect for the reduction of 
blood pressure (up to 5 to 7.5 mg twice daily) and for the presence of side 
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effects (Dahlof 1989; Simonsen & Sundstedt 1989). Similarly, previous reports 
in the literature describe the reduction in exercise performance seen with ~-
blockers as a dose related phenomenon (McKelvie & Jones 1991 ). It is 
possible that the reduction in submaximal exercise performance seen after 
isradipine ingestion in this study is also dose related. If this is so, and had the 
dosages of the 2 medications been equipotent, then the impairment in 
submaximal exercise tolerance after isradipine ingestion may have been 
greater than that seen after atenolol ingestion, and a reduction in maximal 
exercise tolerance may have become apparent. 
Recommendations are constantly being sought as to which anti-hypertensive 
medications are most suitable to patients who are physically active (Chick et al. 
1988; Gordon & Duncan 1991; Houston 1992; Lund-Johansen 1987; Van Baak 
1994). As the effect of many of the first line anti-hypertensive agents, such as 
the newer calcium channel blockers and angiotensin converting enzyme 
inhibitors, on submaximal exercise capacity have yet to be investigated, it is not 
possible to make definite statements that some anti-hypertensive medications 
do not effect exercise capacity. The findings that patients ingesting calcium 
channel blockers generally do not complain of reduced physical capacity 
(Lund-Johansen 1987), and that these agents do not impair maximal exercise 
performance in hypertensive subjects (Ashmore et al. 1990; Fariello et al. 
1991; Gosse et al. 1992; Halperin et al. 1993; Keleman et al. 1989; Pool et al. 
1985; Szlachcic et al. 1987) suggest that calcium channel blockers may indeed 
be a good choice of medication for physically active hypertensive patients. 
However, this study demonstrates that, in subjects who are able to maintain 
regular physical activity while ingesting atenolol or isradipine, isradipine impairs 
submaximal exercise tolerance to the same extent as does atenolol. Therefore, 
in these patients, calcium channel antagonists cannot be recommended above 
atenolol on the basis that they are superior to atenolol in terms of maintaining 
exercise capacity. 
However, despite the fact that the same extent of impairment in prolonged 
submaximal exercise capacity, and a similar increase in RPE during 
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submaximal exercise, was found after isradipine ingestion as after atenolol 
ingestion in this study, the subjective experience of fatigue during physical 
activity was greater after atenolol than after isradipine, as indicated by the 
reported side effects. It may be this subjective experience of fatigue during 
physical activity that determines whether or not physically active hypertensive 
patients will be compliant with their medication. On this basis, it would be 
logical to recommend calcium channel antagonists above ~-blockers for the 
treatment of hypertension in physically active patients. 
Whilst there may be differences in the extent to which different classes of anti-
hypertensive drugs cause impaired exercise performance, there may also be 
differences between drugs of the same class. Non-selective ~-blockers cause a 
greater reduction in submaximal exercise capacity than do ~1-selective 
blockers (Anderson et al. 1985). As described in Chapter 7, a similar 
investigation to this study by Gillies et al. (1996), demonstrated that ingestion 
of the dihydropyridine derivative, amlodipine, did not impair prolonged 
submaximal exercise performance. The discrepancy between the finding by 
Gillies et al. (1996) and the finding that isradipine did impair prolonged 
submaximal exercise performance, underlies the importance of testing the 
effects of each specific medication on exercise performance. 
Recommendations must then be made regarding specific anti-hypertensive 
agents and not a particular class of drug. 
In conclusion, the findings of this thesis are that, in physically active 
hypertensive patients who are able to maintain regular physical activity while 
ingesting atenolol or isradipine, isradipine and atenolol impaired submaximal 
exercise endurance to the same extent. Maximal exercise performance was 
reduced by atenolol only. As most recreational and occupational exercise 
involves submaximal exercise, this demonstrates the necessity to perform 
submaximal exercise testing when assessing the effects of anti-hypertensive 
medications on exercise performance. On the basis of this and other studies 
(Myburgh & Gordon 1987) it is not yet possible to make claims that the calcium 
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channel antagonist agents are without effect on physical exercise performance 
in physically active hypertensive patients. 
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